The source of enteric nervous System progenitor cells present in Aganglionic gut in Hirschsprung’s disease by Bethell, George
The Source of Enteric Nervous 
System Progenitor Cells Present in 
Aganglionic Gut in Hirschsprung’s 
Disease 
 
Thesis submitted in accordance with the requirements 
of the University of Liverpool for the degree of Master 
of Philosophy by 
George Stephen Bethell 
 
 
August 2014 
 Acknowledgments 
Firstly, I would like to thank my supervisors Mr Simon Kenny and Professor David 
Edgar for their help and support over the year and for giving me this opportunity in 
the first place. I would also like to thank Dr David Fawkner-Corbett and Mr David 
Wilkinson for their support at the beginning of the year in the lab and their 
continued mentoring throughout the year. Additionally, Angelica Mesa has been a 
useful collaborator in the lab. 
 
This work would not have been possible without the efforts of the paediatric 
surgeons, pathologists, theatre staff, parents and children of Alder Hey Children’s 
hospital who allowed and assisted in the collection of human tissue samples. 
 
I am also very grateful to the Royal College of Surgeons of England and Champs 
Appeal Hirschsprung’s charity for funding both this project and me personally this 
year. 
 
Finally, I would like to thank my parents for allowing me to undertake another year 
of study and supporting me financially throughout it. 
 
 Abstract 
The source of Enteric Nervous System Progenitor Cells present in 
Aganglionic Gut in Hirschsprung’s disease – George Stephen Bethell 
The enteric nervous system develops predominantly from vagal neural crest cells 
which proliferate and differentiate into enteric neurons and glia whilst migrating to 
the distal gut. Failure of this process for unknown reasons results in Hirschsprung’s 
disease (HSCR) which is characterised by an absence of enteric ganglia in a variable 
length of distal gut. This causes life threatening bowel obstruction and requires 
surgical intervention to remove the affected bowel. Following surgery 10-30% of 
patients suffer from long term constipation or faecal incontinence which can 
worsen with time. 
 
Our group has previously shown that enteric nervous system progenitor cells 
(ENSPC) can be isolated from ganglionic HSCR gut which then differentiate into 
enteric neurons and glia in vitro. Most importantly, these ENSPC form clusters of 
cells known as neurospheres which when implanted into ex vivo aganglionic mouse 
gut, restore normal patterns of contractility. More recently and quite surprisingly, 
ENSPC have also been obtained from aganglionic HSCR gut and behave similarly to 
ganglionic ENSPC in vitro. The aim of this thesis is to add understanding to this 
finding by determining the source of ENSPC in aganglionic HSCR gut. 
 
 The first results chapter focuses on the optimum medium which should be used to 
culture neurospheres. It was found that a horse serum based medium promotes the 
formation of neurospheres under adherent conditions more effectively than a more 
complex medium containing various growth factors.  
 
The next section tests the hypothesis that ENSPC are located within thickened nerve 
trunks in aganglionic gut. Using samples of aganglionic HSCR gut from patients with 
all variants of HSCR it was possible to correlate the presence of thickened nerve 
trunks and the ability to obtain ENSPC as aganglionic gut from total colonic and total 
intestinal HSCR doesn’t contain thickened nerve trunks. It was found that it was not 
possible to obtain ENSPC from aganglionic HSCR gut where thickened nerve trunks 
were absent. This suggests that ENSPC are associated with the thickened nerve 
trunks in aganglionic gut. 
 
Subsequently, experiments were aimed at determining whether aganglionic ENSPC 
are of neural crest lineage. Fluorescence activated cell sorting was used to obtain a 
sub-population of P75 positive neural crest derived cells from freshly dissociated 
aganglionic HSCR gut. After 6 days in culture these cells differentiated into neurons 
whereas this was not the case in the P75 negative sub-population. Finally 
immunohistochemistry was used to look at the structure of thickened nerve trunks 
in aganglionic gut and the expression of P75 is correlated to the possible cellular 
sources of aganglionic ENSPC.  
 When combined, work in this thesis narrows down the possibilities of the cellular 
origin of ENSPC of which the most likely source is cells of Schwann cell lineage 
located within thickened nerve trunks. These findings direct further work and make 
the potential of in vivo ENSPC stimulation and a medical treatment for HSCR more 
possible. 
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 Chapter 1 – Background and introduction 
1.1 Overview 
This chapter starts by introducing Hirschsprung’s disease (HSCR). HSCR is a 
congenital disorder where the enteric nervous system (ENS) has failed to form in a 
variable length of distal gut resulting in tonic contraction in the affected, otherwise 
known as aganglionic, gut. This results in a functional obstruction of the gut and 
dilation of the proximal section, known as megacolon. Most commonly, HSCR is 
suspected if a neonate fails to pass meconium within 24 hours of birth or has 
distension of the abdomen. Diagnosis is confirmed by taking suction biopsies from 
the rectum and the absence of ganglia is looked for. If HSCR is diagnosed the 
definitive treatment is surgical intervention to remove the aganglionic gut in early 
life. Many patients experience lifelong morbidity.  
 
As well as an overview of HSCR, this introduction also covers the function and 
development of the ENS. Finally, work to date, exploring stem cell adjunctive 
therapies for HSCR, is described leading onto the aims of this thesis.  
 
 
 
 
 1.2 Hirschsprung’s Disease  
1.2.1 Introduction 
HSCR is a congenital disorder resulting in aganglionosis of a variable length of distal 
gut with an incidence of 1 in 5000 live births and occurs with a male to female ratio 
of 4:1. Incidence varies between ethnic groups with HSCR being rarer in Hispanics (1 
in 10,000) and relatively more common in Asians with an incidence of 2.8 per 
10,000 live births.(Amiel et al. 2008)  
 
It was initially suspected that genetics had a role in HSCR for a few reasons. Firstly, 
there was an increased incidence in siblings than observed in the general 
population; secondly, the unbalanced sex ratio; thirdly, the association of HSCR with 
other congenital abnormalities and also many reports of mouse models of colonic 
aganglionosis showing Mendelian patterns of inheritance.(Tam & Garcia-Barcelo 
2009) 
 
HSCR is an isolated disorder in 70% of cases however it is associated with other 
congenital abnormalities and termed syndromic HSCR in the remaining 30% of 
cases.(Borrego et al. 2013) In instances where HSCR occurs as an isolated disorder it 
can be split into sporadic disease and familial disease. 
 
 
 1.2.2 Familial and sporadic HSCR 
Familial HSCR accounts for 20% of cases, has a complex pattern of inheritance and 
displays low, sex dependent penetrance. Sporadic HSCR accounts for the remaining 
patients who have the isolated disorder. It is well reported that there is variability in 
the HSCR phenotype despite similar genotypes. In total there are nine different 
genes that are associated with the HSCR phenotype.(Tam & Garcia-Barcelo 2009) 
These are the genes for receptor tyrosine kinase (RET), glial cell line derived 
neurotrophic factor (GDNF), neurturin (NTN), paired-like homeobox 2b (PHOX2B), 
endothelin B receptor (EDNRB), endothelin-3 (EDN3), endothelin converting enzyme 
(ECE1), SRY-related HMG-box (SOX10) and zinc finger homeobox 1b 
(ZFHX1B).(Kenny, Tam & Garcia-Barcelo 2010) 
 
The first gene that is linked with HSCR was initially discovered in the late 1980’s. 
This discovery came about through mouse work and through genotyping patients 
with HSCR. It was found that the HSCR phenotype was present in mice with 
disruption of the RET gene on chromosome 10, it was also found that the RET gene 
mutations were present in families of HSCR patients. Mutations to the RET gene 
account for 50% of familial HSCR cases and 35% of sporadic HSCR.(Tam & Garcia-
Barcelo 2009) RET is a receptor found on enteric nervous system progenitor cells 
(ENSPC), it is vital for normal development of the ENS and is discussed in more 
detail later in this chapter. 
 
 The GDNF gene was first suspected as being involved in HSCR as it is the factor that 
is detected by the RET receptor in the ENS. GDNF has several co-ligands one of 
which is NTN. Work with mice found a similar phenotype between mice with 
knockout of RET and other mice with a knockout of GDNF. There have however 
been no reports of HSCR patients with an isolated mutation to GDNF or NTN. There 
have been very small numbers of HSCR patients reported with a GDNF mutation 
alongside a RET mutation and just one case report of a NTN mutation alongside a 
RET mutation; this was in a familial case.(Kenny, Tam & Garcia-Barcelo 2010; Tam & 
Garcia-Barcelo 2009) There has also been a study where genotyping of patients with 
lower gastrointestinal tract motility disorders such as slow transit constipation 
however there were no mutations to GDNF found in these patients.(Chen et al. 
2002)  
 
PHOX2B encodes for a surface protein expressed by cells of the ENS which is 
essential for RET expression. When homozygous disruption of the PHOX2B gene 
occurs in mice the ENS fails to develop.(Tam & Garcia-Barcelo 2009) In a separate 
study it was reported that mouse embryos with mutation to the PHOX2B gene fail 
to express RET, this is expected due to what is known about the significance of 
RET.(Pattyn et al. 1999) There have been reports of the presence of PHOX2B 
mutation in syndromic HSCR in humans and there is one study which has found the 
association of this gene to non-syndromic HSCR. This study found that a single 
nucleotide polymorphism of PHOX2B is associated with HSCR in a study of 91 
patients. It is thought that this is in the presence of a RET mutation too however 
 this was not looked into and is required to give definitive evidence as to whether an 
isolated PHOX2B mutation can cause HSCR.(Garcia-Barcelo et al. 2003) 
 
The involvement of the EDNRB gene was first demonstrated in mice. Knock outs of 
this gene gave rise to the HSCR phenotype. In humans, mutations of the EDNRB 
gene are found in both isolated and syndromic HSCR, with the syndrome being 
Shah-Waardenburg syndrome. (Kenny, Tam & Garcia-Barcelo 2010) The mutation 
was found to be more penetrant when it was homozygous however this was sex 
dependent. It has also been shown that a heterozygous disruption gives rise to 
isolated HSCR whereas homozygous disruption results in Shah-Waardenburg 
syndrome. The EDNRB gene mutation is usually inherited from unaffected parents 
and results in short segment HSCR. This mutation is only responsible for about 5% 
of cases of HSCR.(Tam & Garcia-Barcelo 2009) 
 
Disruption of the EDN3 gene in mice results in a similar phenotype to disruption of 
the EDNRB gene. This can be expected due to what is known about the signalling 
pathway which includes the receptor and peptide encoded for by these genes and is 
discussed further on in this chapter. Very few mutations to the EDN3 gene have 
been found in patients with HSCR. When they have been found heterozygous 
mutations have given rise to isolated disease whereas homozygous mutations have 
resulted in Shah-Waardenburg syndrome. This is similar to what is seen in 
mutations to the EDNRB gene. A gene closely associated with EDN3 is ECE1 as this 
 encodes for an enzyme which converts EDN3 into its active form. Evidence from 
mouse models show that a knockout of this gene results in the HSCR phenotype 
however this has only ever been associated in HSCR once. This patient had 
syndromic HSCR.(Tam & Garcia-Barcelo 2009) 
 
SOX10 is a transcriptional regulator involved in the development of cell lineage, the 
functions of SOX10 are discussed further on in this chapter. In a mouse model with 
heterozygous knock out of the SOX10 gene the phenotype was very similar to Shah-
Waardenburg syndrome in humans. In humans a heterozygous mutation results in 
Shah-Waardenburg syndrome, showing that this gene is associated with syndromic 
HSCR. There have however been no reports of SOX10 mutations in isolated 
HSCR.(Kenny, Tam & Garcia-Barcelo 2010; Tam & Garcia-Barcelo 2009) 
 
ZFHX1B encodes for a protein that is essential for formation of vagal neural crest 
cells. There are no known mouse studies of this gene. It has been shown that 
mutations to the ZFHX1B gene are present in Mowat Wilson syndrome, a syndrome 
resulting in craniofacial deformities, epilepsy, mental retardation and HSCR. (Kenny, 
Tam & Garcia-Barcelo 2010) There have been no reports of ZFHX1B being involved 
in isolated HSCR. 
 
 
 1.2.3 Syndromic HSCR 
HSCR is associated with chromosomal anomalies or congenital abnormality in 30% 
of cases. Of the chromosomal abnormalities trisomy 21, also known as Down 
syndrome, is most commonly associated with HSCR. This has led to work looking at 
the over expression of genes on chromosome 21, related to the development of the 
ENS however there have been limited data produced from these studies so far. It is 
known however that the RET hypomorphic allele, which causes HSCR, is more 
common in patients with trisomy 21.(Amiel et al. 2008)  
 
HSCR is associated with other neurocristopathies, this is congenital disease due to 
failure of migration, proliferation, differentiation or survival of neural crest cells 
(NCC). This is predictable due to the development of the ENS and will be discussed 
later in this chapter. It is particularly important to promptly identify multiple 
endocrine neoplasia syndrome type 2B associated with HSCR, which is one of the 
neurocristopathies, by genetic screening due to the risk that medullary thyroid 
carcinoma poses.(Kenny, Tam & Garcia-Barcelo 2010) 
 
 
 
 
 
 1.2.4 Classification 
HSCR is classified on the length of gut affected by the disease. Short segment 
disease does not extend proximal to the rectosigmoid junction of the large 
intestine, this accounts for over 80% of cases.(Obermayr et al. 2013) Long segment 
disease extends proximally beyond the rectosigmoid junction and has an incidence 
of 15-20%. In total colonic disease the whole of the large intestine is affected, this 
accounts for 5% of HSCR. A very rare variant of HSCR is total intestinal aganglionosis 
which extends at least to the duodenum and has even been reported to extend to 
the oesophagus, this is seen in around 1 in 500,000 live births.(Bergeron, Silversides 
& Pilon 2013; Ruttenstock & Puri 2009) Interestingly, the male to female gender 
bias in short segment disease is 4:1, in long segment disease it is 2:1 and it is lost in 
total colonic and total intestinal aganglionosis.(Borrego et al. 2013; Kenny, Tam & 
Garcia-Barcelo 2010) 
 
 
 
 
 
 
 
 
 1.2.5 History 
The first observation of the disease may have been reported in 1691 by a Dutch 
anatomist called Frederick Ruysh.(Cass 1986) He described a case where a five year 
old presented with abdominal pain and did not respond to the “usual treatment” of 
the time which was not documented. She subsequently died and on post mortem a 
megacolon was seen. Although there a many unknowns regarding this case there is 
a suspicion that this is the first documented case of HSCR. 
 
There were various similar reports over the years until in 1901 Tittel, an Austrian 
physician reported the first histological study of one of these patients. He reported 
“sparse development of the plexuses throughout the colon, but normal findings in 
the ileum”.(Tittel 1901)  
 
In 1904 Harald Hirschsprung wrote a chapter in a textbook dedicated to congenital 
dilation of the colon and described 10 patients who had “congenital dilation of the 
colon”. Five of the ten patients died before 12 months of life. In all of the patients 
who underwent post mortem, dilated and hypertrophied gut was described. It was 
also confirmed that there was no obvious mechanical obstruction however there 
was little thought at this point into the aetiology of the disease. It was however 
recognised as a congenital abnormality.(Holschneider 2008) 
 
 In 1920 a case report was produced detailing the absence of nerve ganglia in the 
sigmoid colon but presence of ganglia in more proximal colon in two brothers. This 
triggered thought into the aetiology of the disease and many trials using rodents 
took place to show that the megacolon was in fact due to the absence of the ENS in 
distal colon, giving the first understanding of the pathological process which caused 
HSCR.(Holschneider 2008)  
 
In 1948 Swenson discovered, by use of a barium enema and fluoroscopy in patients 
with HSCR, that there was spasm in a section of gut in these patients. This defined 
the level of obstruction and added further information to the process causing 
megacolon in HSCR patients.(Holschneider 2008; Swenson 1999) In the same year 
the abnormal histological findings were correlated to the abnormal physiological 
findings in the affected gut and HSCR was recognised histopathologically as the 
absence of ENS ganglia. (Zuelzer & Wilson 1948) 
 
The subsequent key events in the history of HSCR involve the evolution of surgical 
techniques used to treat the disease. This is discussed in detail in the management 
section further on in this chapter. 
 
 
 
 1.2.6 Pathology 
HSCR is caused by failure of development of the ENS, causing aganglionosis, in a 
variable length of distal gut. There may be one pathophysiology for all cases of 
HSCR or different pathophysiologies depending on the length of aganglionosis 
present. Current thought is that functional enteric neural crest cells (ENCC) have 
failed to migrate along the full length of the gut. Another theory has come about 
from previous work from our group looking at aganglionic gut from HSCR 
patients.(Wilkinson et al. 2013) This is that the ENCC have migrated but have failed 
to differentiate into functional ganglia. This is discussed in more detail later on in 
this chapter.  
 
In HSCR, the affected length of gut causes a functional obstruction of the contents 
of the gastrointestinal (GI) tract as the lack of inhibitory innervation results in tonic 
contraction of the smooth muscle in the two muscular layers of the gut. The result 
of this is visible at surgery as the proximal section of gut is dilated due to the 
obstruction and is sometimes described as ‘megacolon’.  
 
In the aganglionic segment of gut in HSCR there is an absence of myenteric and 
submucosal ganglia and presence of hypertrophied extrinsic nerve trunks which 
originate from the pelvic plexus in short and long segment HSCR.(Okamoto, Satani 
& Kuwata 1982) In long segment HSCR there are a reduced number of thickened 
trunks observed compared to short segment HSCR on histology for reasons 
 unknown at this point in time.(Watanabe et al. 1998) In total colonic disease there 
is a total absence of thickened nerve trunks in aganglionic gut, this is also the case 
in total intestinal aganglionosis. Subsequently, interstitial cells of Cajal are also 
usually absent from the muscular layers in aganglionic total colonic and total 
intestinal HSCR gut but are present in the same layers in short and long segment 
HSCR gut.(Solari, Piotrowska & Puri 2003) 
 
This raises questions on the pathophysiology behind total colonic and total 
intestinal disease as there are major histological differences in these patients 
compared to short and long segment disease in regards to the thickened nerve 
trunks.  
 
Very little is known about the formation, presence and function of thickened nerve 
trunks. One unpublished theory that might explain the presence of these thickened 
trunks in aganglionic gut in short and long segment HSCR is that the ENS normally 
inhibits the growth of the extrinsic nerve trunks within the myenteric plexus and 
submucosal plexus. Therefore when the ENS is not present there is overgrowth of 
these nerves.  
 
 
 
 1.2.7 Clinical presentation 
The typical presentation of HSCR is when a neonate fails to pass meconium within 
the first 24 hours of life. The neonate can also develop life threatening bowel 
obstruction with necrotising enterocolitis due to the build of faeces and bacterial 
overgrowth within the gut. It is also possible, particularly with short segment 
disease, for a patient to present later on in childhood or very rarely in their early 
teenage years with chronic constipation.(Arshad, Powell & Tighe 2012) 
 
Antenatal screening is currently not used to screen for HSCR. It would be possible to 
genotype a foetus antenatally however this involves invasive tests which would only 
be carried out on suspicion of some other congenital abnormality. It is not possible 
to detect HSCR on a foetal ultrasound scan. Even if it was possible to identify HSCR 
genetically the extent of aganglionosis and prognostic factors such as likely 
response to surgery would be unknown and hence there is little argument regarding 
a benefit to discovering HSCR antenatally. 
 
 
 
 
 
 
 1.2.8 Investigations 
If HSCR is suspected rectal suction biopsies from 2cm above the dentate line are 
taken, an adequate biopsy must include the submucosal tissue layer, which in 
normally innervated gut would include the submucosal plexus. Histopathological 
staining then takes place to attempt to identify an increased activity of 
acetylcholinesterase which is present within the thickened nerve trunks within the 
muscular layers in HSCR.(de Arruda Lourencao et al. 2013) The presence or absence 
of ganglia is also assessed using haematoxylin and eosin staining. This is particularly 
important as it will differentiate total colonic and total intestinal HSCR from 
normally innervated gut.(De Lorijn et al. 2005) The limitation of this investigation is 
that it is superficial and does not take tissue from below the submucosal layer of 
the rectum.  
 
To confirm the diagnosis several full thickness biopsies, including both muscular 
layers of the gut, are taken under general anaesthesia at the time of surgery for 
HSCR. The biopsy is sent fresh to the laboratory during the procedure and 
acetylcholinesterase staining takes place, as with the suction biopsies. Once a 
definite diagnosis is given the level of the aganglionosis can be determined as the 
several biopsies at various lengths along the dilated gut will reveal this information. 
Once this is known surgery can continue as the aganglionic gut to be resected has 
been determined histologically.(De Lorijn et al. 2005) 
 
 1.2.9 Treatment  
Treatment for short and long segment disease consists of removal of the affected 
length of gut by one of three techniques. In total colonic disease there are various 
approaches to treatment however most commonly treatment involves a total 
colectomy with the formation of a distal ileostomy or the formation of an ileal 
pouch. Outcomes are poor for these patients and the majority experience lifelong 
morbidity.(Moore 2012) In more extensive aganglionosis a jejunostomy is usually 
formed and the patient must rely on a small gut transplant for any chance of 
survival beyond the neonatal period.(Bond & Reyes 2004) The aim of any definitive 
surgical intervention is to remove the dysfunctional gut which includes the 
aganglionic gut and the transition zone, leaving only ganglionic gut (Diagram 1.1). 
 
Diagram 1.1. Schematic showing gut resected in definitive surgery for HSCR. Areas 
shaded in grey show gut resected and areas in green shows gut spared during 
surgery. 
 
 The three surgical techniques for HSCR are the Swenson, the Duhamel and the 
Soave procedures. 
 
1.2.9.1 Swenson procedure 
The Swenson procedure was the first definitive treatment for HSCR and was first 
described in 1948.(Swenson & Bill 1948) After the level of aganglionosis is 
determined, the distal colon is mobilised by laparotomy and resection down to the 
anal canal takes place. The aganglionic section of colon is then removed and the 
ganglionic colon is anastomosed to the anal canal. This procedure is considered as 
very invasive and carries a large risk to nearby urogenital structures including the 
autonomic plexus. The internal anal sphincter is also removed in this procedure. 
Due to the risks that this procedure carried other techniques were developed. 
 
Recently however this technique has been revisited and adapted so that a full-
thickness dissection occurs via the anus. This isn’t common practice but the 
outcomes from one centre report that the technique is as desirable as the other 
more modern techniques.(Levitt et al. 2013) 
 
1.2.9.2 Duhamel procedure 
The Duhamel technique was originally described in 1956.(Duhamel 1956) The 
advantages of this procedure over the Swenson procedure was that the internal 
 anal sphincter was left intact which was thought to give a lower risk of long term 
complications. This was accomplished by commencing the full thickness dissection a 
few centimetres above the dentate line. The resection via the abdominal route was 
also only into the rectal pouch hence avoiding trauma to the urogenital organs. The 
aganglionic gut is resected and an anastomosis takes place between the aganglionic 
colon and the remaining few centimetres of rectum.  
 
Since 1956 the main modification to this technique has been the introduction of a 
stapler to form a longitudinal anastomosis via the anus at operation.(Steichen, 
Spigland & Nunez 1987) 
 
1.2.9.3 Soave procedure 
In 1964 Soave developed a technique for treating HSCR that involved a more 
superficial dissection and was undertaken by a transanal approach.(Soave 1964) The 
dissection started a few centimetres above the dentate line and was only as deep as 
the submucosal layer of the rectum. The dissection then continues moving 
proximally for another 3-4cm before the dissection becomes full thickness. The 
aganglionic section of gut is then removed via the transabdominal route and 
resected. This technique has the advantage of leaving an aganglionic muscular cuff 
in which the pulled through ganglionic gut sits on top of. Therefore there is less risk 
of damage to the organs of the pelvis. Originally the anastomosis between the 
 rectum and the ganglionic colon was delayed for 10 days before taking place via a 
subsequent laparotomy.  
 
Later on in 1964 Boley modified the Soave technique and reported the use of a 
primary anastomosis instead of delaying it as Soave had originally described.(Boley 
1964) This has led to the Soave procedure becoming commonly known as the 
Soave-Boley procedure.  
 
In 1996 Saltzman reported a transanal pull through of the aganglionic gut with 
primary anastomosis.(Saltzman et al. 1996) The major advantage of this 
modification was a shorter operating time as the transanal dissection can occur at 
the same time as the biopsies are obtained with laparotomy. A shorter stay 
postoperatively was also reported, although there were no suggestions as to why 
this was the case. 
 
Finally in 1999 a laparoscopic assisted transanal pull through with primary 
anastomosis was described.(Georgeson et al. 1999) This carried the same 
advantages as Saltzman had reported but with the additional benefits that 
laparoscopic surgery brings. 
 
 
 1.2.9.4 Current practice 
In 2011 every paediatric surgeon in the UK and Ireland who operated on children 
with HSCR was surveyed.(Bradnock & Walker 2011) There were 64 respondents in 
total from 21 of the 26 tertiary paediatric surgery centres. Only 40 of the 
respondents routinely performed definitive surgery for HSCR giving a median of 5 
(range 1.5-16) procedures per year per consultant. 35 out of the 40 consultants aim 
to operate on a neonate at less than 3 months of age. The Duhamel procedure was 
the technique of choice for 18 of the 40 surgeons with the Soave-Boley technique 
being favoured for the other 22 surgeons. No surgeons favoured using the historical 
Swenson technique. Remarkably only 18 of the 40 surgeons used a laparoscopic 
assisted approach. 
 
The authors of the paper reporting this survey and compared their work to a similar 
study(Huddart 1998) which was published eleven years before theirs. The major 
changes that occurred over the eleven year time period was the increase in the 
number of surgeons willing to operate on neonates younger than 3 months (46% v 
88%). The amount of paediatric surgeons operating on HSCR patients also increased 
from 41% in 1998 to 85% in 2011. The use of laparoscopy and the Soave-Boley 
technique has also increased over this time period. 
 
Some surgeons are only seeing a handful of these patients per year as there are a 
large proportion of surgeons operating on patients with HSCR. There have therefore 
 been suggestions that fewer surgeons should operate on these patients and that 
subspecialisation should occur in all units. The main thought behind this is that 
there are bound to be better outcomes for the patients however there is currently 
no long term outcome data available to support this.(Bradnock & Walker 2011) 
 
1.2.10 Complications  
Short term complications for all surgical HSCR procedures include enterocolitis, 
anastomotic leak and strictures. Most worryingly however are the long term 
complications that can result in lifelong morbidity. 
 
The limitation of current surgery is that the internal anal sphincter, which is 
supplied by the ENS, is not removed and is anastomosed to the ganglionic gut. This 
results in the aganglionic internal anal sphincter failing to relax and contract as it 
should do in normally innervated gut. Therefore, between 10% and 30% of patients 
suffer from lifelong morbidity due to either faecal incontinence or chronic 
constipation.(Wilkinson, Edgar & Kenny 2012) There is also evidence which shows 
that complications worsen as the patient grows older.(Jarvi et al. 2010) Chronic 
constipation can be improved with regular Botulinum toxin injections targeted at 
the internal anal sphincter. Unfortunately, results vary from patient to patient and 
more work is needed to understand who benefits best from this 
treatment.(Koivusalo, Pakarinen & Rintala 2009) For the patients who suffer from 
faecal incontinence there are various strategies which are used. These include 
 changes to diet to avoid certain foods such as fatty foods, the usage of laxatives (to 
treat pseudo diarrhoea), rectal washouts and also anti-diarrhoeal 
medication.(Catto-Smith, Trajanovska & Taylor 2007) Some patients, particularly 
those with anastomotic strictures require reoperation on the muscular cuff left with 
the Soave procedure.(Dickie et al. 2014) Despite attempts to treat these 
complications, 10% of these patients require a permanent colostomy due to the 
severity of their symptoms.(Baillie et al. 1999)  
 
 
 
 
 
 
 
 
 
 
 
 
 1.3 The Enteric Nervous System 
1.3.1 Introduction 
The ENS is an extensive network of neurons and glia which are present within the GI 
tract and innervate the gut. Its main function is to control the motility of ingested 
food through the gut along with the control of absorption and secretion, of 
nutrients and electrolytes.  
 
1.3.2 Structure of the ENS 
In humans there are approximately 400-600 million neurons within the ENS which 
group together forming ganglia. These ganglia are located and confined to two 
separate layers of the gut wall, the myenteric plexus and the submucosal 
plexus.(Obermayr et al. 2013) Along with connections between the ganglia in each 
plexus enteric nerves extend into and through the muscular layers to connect the 
two nervous layers. In addition to this nerves also extend to the mucosal 
layer.(Gulbransen & Sharkey 2012) 
 
1.3.3 Function of the ENS 
The ENS has several important functions. Firstly, it innervates the smooth, circular 
and longitudinal muscle of the GI tract from the oesophagus through to the internal 
anal sphincter therefore controlling, through reflex pathways, peristalsis of 
 digesting food along the GI tract. The ENS is also responsible for controlling both 
water and electrolyte secretion and absorption, along with blood flow, throughout 
the GI tract.  
 
Smooth muscle sphincters along the GI tract are also controlled by the ENS, 
including the internal anal sphincter which is vital for continence and normal 
defecation. The ENS has both sympathetic and parasympathetic innervation from 
extrinsic pelvic nerves. When the sympathetic pathway is activated passage of the 
contents of the GI tract is restricted by inhibition of the muscular layers. Blood 
supply, fluid secretion and electrolyte secretion is also reduced. With increased 
sympathetic innervation the sphincters of the tract which are controlled by the ENS 
contract. Parasympathetic innervation produces opposite consequences to 
sympathetic innervation.(Furness 2008)  
 
In terms of differing functions between the two layers it is thought that the 
myenteric plexus (located as a layer between the longitudinal and circular muscle) 
has a larger role in motility than the submucosal plexus which oversees absorption 
and secretion.(Hall & Guyton 2011; Jiang, Liu & Gershon 2003) 
 
 
 
 1.3.4 Development of the Enteric Nervous System 
The ENS is formed from NCC which have migrated into the foregut, as they are 
migrating they are also proliferating and to some extent differentiating. Migration 
continues to the distal hindgut in order to colonise the entire gut with ENSPC which 
give rise to the mature ENS. 
 
1.3.4.1 Migration and proliferation of Neural Crest Cells 
There are five different populations of NCC within the developing embryo; these are 
the cranial, trunk, cardiac, vagal and sacral NCC. The populations relevant to the 
ENS are the vagal and sacral NCC. Ablation studies of NCC in chicks have shown that 
the majority of the contribution to the ENS is by the vagal crest, which is formed 
adjacent to somites one to seven.(Bergeron, Silversides & Pilon 2013; Wallace & 
Burns 2005) In addition to the colonisation by vagal NCC, there is also migration in 
the caudal to rostral direction of sacral NCC, which are found adjacent to somites 28 
onwards. This has been shown using a quail-chick chimera system and sacral NCC 
were found to only colonise the gut beyond the umbilical portion. (Obermayr et al. 
2013) It has been shown that these sacral NCC rely on contact with the vagal NCC 
before the sacral NCC spread rostrally within the gut.(Sasselli, Pachnis & Burns 
2012) Therefore sacral cells cannot contribute to the development of the ENS 
without the presence of vagal NCC in the distal gut. Furthermore, the axons of 
extrinsic neurons migrate into the distal hindgut from the pelvic plexus with the 
 sacral NCC but the signalling pathways involved with this are unknown.(Erickson et 
al. 2012; Wang et al. 2011) 
 
Once the vagal and sacral NCC migrate from the hindbrain into the foregut they are 
termed ENCC. These ENCC colonise the gut as far as and including the internal anal 
sphincter travelling in the rostral caudal direction within the 
mesenchyme.(Bergeron, Silversides & Pilon 2013) These ENCC migrate through the 
gut in cords of connected cells forming a migratory wave front.(Conner et al. 2003) 
Studies using mice embryos have shown that the migration to the caecum is a 
continuous process of advancing cells arranged in cords provided there is a 
sufficient number of ENCC present. If only a small number of these cells are in the 
gut then there is an arrest in migration.(Druckenbrod & Epstein 2005) At the 
caecum a different pattern of migration is seen, the wave front becomes static for 
around 8-12 hours during which some ENCC advance as isolated cells into the 
proximal colon. The isolated cells then form groups so that there are a number of 
isolated small populations of cells. Strands then form between these groups and 
migration continues as a continuous wave to the distal colon, colonising the full 
length of the gut.  
 
In mouse studies, this unique process in the caecum has been shown to be due to 
specific signalling of the caecal mesenchyme. This signalling occurs by the release of 
various factors which act upon the ENCC. Fibroblast growth factor 10 (FGF-10) is 
 responsible for the growth of caecal epithelium, the superficially layer of the 
caecum, which is the section of gut between the ileum and ascending colon. It is 
unique to the caecum.(Burns, Pasricha & Young 2004; Druckenbrod & Epstein 2005) 
Bone morphogenic factor 4 (BMP4) has been shown to stimulate the development 
of enteric neurons as well as reduce the size of the progenitor pool.(Chalazonitis 
2004; Druckenbrod & Epstein 2005) There are also increased levels of GDNF and 
EDN3 released from the caecal mesenchymal cells. GDNF is a chemo-attractant for 
ENCC whilst EDN3 inhibits the actions of GDNF. This may explain how the 
population is arrested in their migration within the caecum. The presence of GDNF 
prevents ENCC continuing their migration as they have done up to the caecum. The 
increase of EDN3 signalling, 8-12 hours later, may inhibit the stasis of these cells 
within the caecum and hence allow the continuation of migration into and beyond 
the proximal colon.(Druckenbrod & Epstein 2005)  
 
Another source of isolated advancing cells in the colon is from ENCC that have 
crossed the mesentery from the small intestine.(Druckenbrod & Epstein 2005) In 
humans and mice the mid small intestine and proximal colon are transiently 
juxtaposed during normal gut development. This happens during the rotation and 
physiological herniation of the mid gut and takes place between weeks 4 and 8 of 
gestation in humans. The mid gut herniates into the proximal umbilical coelom and 
then rotates 90o anticlockwise around the vitelline duct. The herniated mid gut then 
returns to the abdominal cavity whilst rotating a further 180o anticlockwise. The gut 
now lies in the correct orientation after a total of 270o rotation. Following this 
 embryological process in mice it has been found that ENCC are present in the 
mesentery between these two sections of gut.(Coventry et al. 1994; Obermayr et al. 
2013) It has been shown that a substantial proportion of ENCC in the colon are from 
this anatomical shortcut from the small gut. It has been shows that the GDNF-RET 
signalling pathway has a role to play in this process.(Nishiyama et al. 2012) This 
work suggests that the rotation of the mid gut is not only required to give rise to 
normal, mature anatomy in this region but to also allow colonisation of the distal 
gut tube with ENCC in order to give rise to the ENS. 
 
In addition to longitudinal migration there must also be movement of ENCC 
centripetally. In mice, rats and chicks ENCC migrate once they are present in the 
superficial layer (which will become the myenteric plexus) into the deeper, 
submucosal plexus so that both layers are innervated. This is shown to be regulated 
by Netrin which is a protein which guides axon development.(Jiang, Liu & Gershon 
2003)  
 
The colonisation of the entire gut is a relatively lengthy process and takes seven 
weeks in humans. NCC enter the proximal gut at week five of gestation, the now 
termed ENCC reach the terminal ileum at week seven and finally reach the distal 
rectum at week twelve of gestation.(Fu et al. 2004) In mice this process takes 
around 5 days and starts with NCC entering the foregut at day 9 of gestation, the 
ENCC reach the caecal region at day 11.5 and reach the distal rectum by day 14.5 of 
 gestation.(Young et al. 1998) The average gestation of a mouse is 20 days. As 
discussed, the whole process is regulated by cell surface molecules expressed by the 
migrating ENCC along with factors secreted by the mesenchymal cells.(Obermayr et 
al. 2013) As well as migrating, the cells are also proliferating and differentiating into 
neurons and glial cells. This is a continuous process, which starts as soon as NCC 
enter the foregut.(Anderson et al. 2007) 
 
1.3.4.2 GDNF-RET pathway 
The most important signalling pathway within the development of the ENS is the 
GDNF-RET pathway. GDNF is produced by mesenchymal cells within the developing 
gut and RET is a tyrosine kinase receptor which is expressed by ENCC.(Obermayr et 
al. 2013) The interaction between the RET receptors and GDNF is regulated by 
glycosyl-phosphatidyl-inositol linked cell surface glycoproteins (GFRα1-4).(Barlow, 
de Graaff & Pachnis 2003) In studies using mouse models where knockout of the 
RET, GDNF and GFRα1 have occurred total aganglionosis of the gut results. Whereas 
hypomorphic mutation results in partial aganglionosis in mice, which can be used as 
a model of HSCR.(Barlow, de Graaff & Pachnis 2003; Cacalano et al. 1998; Moore et 
al. 1996; Pichel et al. 1996) 
 
Signalling between GDNF and RET is essential for survival, proliferation, migration 
and differentiation of ENCC. GDNF is expressed by the mesenchyme from the 
foregut to the caecum. The concentration of GDNF within different sections along 
 the gut vary over time producing a concentration gradient in the caudal rostral 
direction. This keeps the ENCC moving towards the distal gut and prevents stasis 
except for in the caecum as mentioned previously. Despite this it is thought that 
GDNF does not have a role in attracting NCC to the foregut in the first place as 
experiments in RET knockout mice found that these cells die as they reach the 
foregut instead of before. Therefore GDNF-RET interaction is exclusive to 
ENCC.(Natarajan et al. 2002; Young et al. 2001)  
 
There are numerous transcription factors but most notably SOX10 and PHOX2B that 
are needed for the expression of RET, therefore failure of production of these 
factors results in failure of the GDNF-RET pathway.(Southard-Smith, Kos & Pavan 
1998)  
 
As well as positive regulators of RET there are two negative regulators which are 
required to avoid over expression of RET and the resultant hyperganglionosis. These 
regulators, Sprouty 2 and the Kinesin superfamily protein 26A (KIF26A), have an 
important role in determining the total number of neurons.(Taketomi et al. 2005; 
Zhou et al. 2009) This has been shown in a mouse model. Mice with knock outs of 
the genes responsible for these factors develop up to 50% more neurons in the gut. 
This hyperganglionosis also results in megacolon, as already mentioned a dilation of 
the gut due to the accumulation of gut contents proximal to an obstruction, and 
oesophageal achalasia. Oesophageal achalasia is a disorder of motility where the 
 primary problem in that the lower oesophageal sphincter fails to relax along with 
absence of peristalsis. This is thought to be caused by an imbalance to the complex 
excitatory and inhibitory mechanisms within the ENS due to the 
hyperganglionosis.(Taketomi et al. 2005) 
 
Another cause of hyperganglionosis is the deletion of the phosphatase and tensin 
homolog (PTEN) gene which is responsible for a phosphatase which controls cell 
growth, proliferation and death. In a mouse model involving the deletion of this 
gene, megacolon and intestinal pseudo obstruction occurred which resulted in 
death at around two to three weeks after birth.(Puig et al. 2009) This is most likely 
due to failure of normal neural cell apoptosis during development and hence the 
result is hyperganglionosis. It is also known that there is crosstalk between the PTEN 
and the RET pathway.(Zbuk & Eng 2007) 
 
It is clear that pathology occurs with hyperganglionosis as well aganglionosis, hence 
this has to be considered when developing any ENS stem cell therapy to ensure that 
hyperganglionosis does not occur.  
 
1.3.4.3 Differentiation of enteric neural crest cells 
It has been shown in mouse models that neurogenesis occurs within 24 hours of 
ENCC entering the foregut. This process of differentiation into neurons and glial 
 cells continues into the postnatal period. In mice, this process stops at around 3 
months of life and does not normally continue into the adult period. Neurogenesis 
has however been shown to continue in the adult period as a response to ENS injury 
and is regulated by 5-hydroxytryptamine 4 receptors.(Laranjeira et al. 2011; 
Obermayr et al. 2013) 
 
Many of the chemical factors which influence ENCC migration also affect cellular 
differentiation. There are various molecules produced by the gut mesenchyme that 
promote the differentiation of the ENCC, to note these are GDNF, neurotrophin 3 
and bone morphogenetic proteins including BMP4.(Obermayr et al. 2013) There is 
also one factor that inhibits the differentiation of ENCC as shown in mouse studies. 
This is EDN3 and its function is to prevent premature differentiation of ENCC whilst 
they are still migrating in order to preserve the progenitor pool.(Wu et al. 1999) 
 
There are also transcription factors expressed by ENCC that have a role in the 
differentiation of ENCC within the primitive gut. SOX10 inhibits ENCC differentiation 
and is expressed by all NCC as they migrate towards the foregut. Once the cells 
enter the foregut PHOX2B and Achaete scute homolog 1 (ASCL1) are also expressed. 
The expression of these two factors once the NCC have entered the gut causes 
inhibition of SOX10. Therefore an enhanced expression of SOX10 prevents the 
differentiation of NCC and a reduced expression of SOX10 results in premature 
 neurogenesis and gliogeneis.(Obermayr et al. 2013; Sasselli, Pachnis & Burns 2012) 
To note, SOX10 is also expressed by mature Schwann cells. 
 
1.3.4.4 EDN3-EDNRB pathway 
As stated, NCC start to differentiate into mature neurons and glial cells within 24 
hours of entering the foregut in mice. This is regulated by EDN3 which is a signalling 
factor produced by gut mesenchyme that interacts directly with the EDNRB on 
ENCC. In mice with a knock-out of the gene coding for EDNRB an increased rate of 
differentiation of the ENCC is seen. This reduces the amount of immature 
progenitor cells present in the gut resulting in arrest in migration and hence 
aganglionosis is seen in the distal gut.(Obermayr et al. 2013) The distal gut is only 
affected as this pathway is required for terminal ENCC migration and not the initial 
attraction or migration within the foregut and midgut.(Lee, Levorse & Shin 2003) 
 
 
 
 
 
 
 
 1.4 A stem cell adjunctive therapy to HSCR 
1.4.1 Introduction 
Despite the development of many surgical options for patients with HSCR, current 
treatment is associated with lifelong morbidity for many patients.(Baillie et al. 1999; 
Jarvi et al. 2010; Wilkinson, Edgar & Kenny 2012) Therefore, research is needed 
which looks at the prevention of long term constipation and faecal incontinence 
which many HSCR patients suffer from. 
 
Work undertaken by our group previously has explored the feasibility of generating 
an ENS in vivo with the use of ENSPC to reinstate normal patterns of contractility 
within the gut of patients with HSCR. It is thought that his would prevent long term 
postoperative morbidity. Mouse and human tissue has been used previously and is 
detailed in this section.  
 
To avoid immunological rejection issues autologous implantation is considered the 
best approach. It is also thought that a stem cell therapy would best function as an 
adjunctive therapy to surgery for the reason that it would be very difficult to 
colonise the entire gut with progenitor cells however it would be possible to 
colonise a small but functionally important area, such as the internal anal sphincter.  
 
 
 1.4.2 Characteristics of ENSPC obtained from embryonic mouse 
In recent years, ENSPC were isolated from embryonic mouse gut. These cells were 
shown to differentiate in vitro into enteric neurons and glia and form neurospheres. 
A neurosphere is a self-adherent cluster of neural stem cells, progenitor cells and 
their progeny which were originally cultured from cells derived from the central 
nervous system before groups such as ours have been able to culture enteric 
neurospheres.(Uchida et al. 2000) In addition, these enteric neurospheres were 
implanted into ex vivo mouse gut. Following time in culture proliferation, migration 
and differentiation of ENSPC into neurons and glia was observed within the ex vivo 
gut.(Almond et al. 2007) Most importantly, when these neurospheres were 
implanted into ex vivo aganglionic mouse gut, high frequency contractions were 
restored which showed the ability of ENSPC to develop a functional ENS in 
vitro.(Lindley et al. 2008) 
 
The next step was to translate this work to experiments using human enteric 
neurospheres containing ENSPC. 
 
1.4.3 Characteristics of ENSPC obtained from human neonatal gut 
Cells were obtained from human neonatal gut and neurospheres were generated in 
culture. As with the embryonic mouse neurospheres, human neurosphere 
transplantation into ex vivo mouse gut allowed ENSPC migration and differentiation 
 into neurons and glia.(Almond et al. 2007) Most importantly human neurospheres 
were also shown to restore normal patterns of smooth muscle contractility in 
aganglionic ex vivo mouse gut by forming functional synapses to the native smooth 
muscle.(Lindley et al. 2008) These findings were also identical in neurospheres 
formed from cells obtained from ganglionic HSCR gut. 
 
The next step involved developing a sufficient quantity of neurospheres as the 
number of primary neurospheres that were cultured was relatively low. This 
involved dissociating primary neurospheres and allowing secondary neurospheres 
to form. This was then repeated to produce tertiary neurospheres. This resulted in 
exponential growth from ten primary neurospheres to around 300 tertiary 
neurospheres. Each generation of neurospheres were found to have similar 
characteristics in terms of size and neuronal marker immunoreactivity using PGP9.5. 
This is important as it shows that it is possible to generate a large number of 
neurospheres which is required for a stem cell therapy for HSCR using neurosphere 
implantation.(Lindley et al. 2009) 
 
It was assumed from previous experiments that neurospheres contained progenitor 
cells and provided an environment for progenitor cell proliferation. However it was 
not known how the cells behaved within the neurosphere formation. Further 
experiments found that ENSPC rapidly proliferate on the surface of the neurosphere 
before moving towards the centre. After 8 days in the centre these progenitor cells 
 started to show a neural phenotype. Notch signalling was inhibited in cells within 
neurospheres by inhibiting a notch signalling peptide which resulted in a reduction 
in proliferation to 55% compared to the controls. Differentiation subsequently 
increased, this was identified by increased expression of the neuron markers Tuj 
and NOS. It was concluded that Notch signalling was responsible for progenitor cell 
proliferation and inhibition of progenitor cell differentiation in the periphery of the 
neurosphere.(Theocharatos et al. 2013) This is significant as a failure of notch 
signalling in an embryo may be result in a reduced progenitor pool and premature 
development of the ENS before cells have migrated to the distal hindgut causing 
HSCR. Another implication of this finding is that it may be possible to control ENSPC 
within neurospheres once implanted into aganglionic gut by inhibiting Notch 
signalling. This would stimulate the differentiation of cells and limit proliferation 
which is required for development of the ENS. Most importantly, differentiated cells 
are safer compared to un-differentiated progenitor cells in terms of their ability to 
form tumours. This is a concern with any stem cell therapy and could be 
marginalised with in vivo Notch signalling inhibition. 
 
1.4.4 Human ENSPC from aganglionic HSCR gut 
Most recently, and quite remarkably, neurospheres have been cultured from cells 
obtained from aganglionic short and long segment HSCR gut. These aganglionic 
neurospheres were then compared to neurospheres formed from cells obtained 
from ganglionic HSCR gut. It was found that there is a similar proportion of smooth 
muscle, neural crest derived cells and mature neurons in both types of neurosphere 
 over four time points. Neurospheres from aganglionic gut were also implanted into 
aganglionic, ex vivo mouse gut and normal patterns of contractility were 
restored.(Wilkinson et al. 2013)  
 
This finding has important implications. Firstly, aganglionic gut obtained at pull 
through procedure can be used as a source of ENSPC which can be cultured into 
neurospheres and implanted into the remaining aganglionic internal anal sphincter. 
This avoids the requirement to resect ganglionic gut in HSCR patients to use as a 
source of ENSPC for stem cell therapy. However, most interestingly this work raises 
a new question which is whether ENSPC can be stimulated within the aganglionic 
HSCR gut in vivo to proliferate and differentiate into a functional ENS. In order to 
explore this further the molecular cues which trigger ENSPC proliferation and 
differentiation must be understood. Ultimately, further work in this area could lead 
to a therapeutic treatment for HSCR and surgical intervention could be avoided all 
together. 
  
In order to explore the use of aganglionic ENSPC for stem cell therapy for HSCR the 
source of these cells needs to be understood, predominantly for safety reasons and 
also to improve the efficacy of a stem cell therapy. There are three likely 
possibilities. Firstly, it may be that ENCC have migrated to the distal gut during 
development but have failed to differentiate into a functional ENS. Hence, they 
have remained in an undifferentiated state until exposed to culture conditions. 
 Secondly, that a cell type located within the thickened nerve trunks which is the 
only neuronal tissue in aganglionic HSCR gut, acts as ENSPC. Lastly, it may be 
possible that ENSPC obtained from aganglionic HSCR gut are of non neural crest 
lineage and when these cells are exposed to culture conditions they are able to 
differentiate into enteric neurons and glia.  
 
As well as understanding the source and cellular origin of ENSPC in aganglionic gut 
the reason why these cells have failed to form an ENS when they are present in the 
tissue must also be answered in order to understand how these cells can be 
stimulated in vivo. 
 
 
 
 
 
 
 
 
 
 
 1.5 Aims of the thesis 
Overall the aim of this thesis is to confirm the finding that it is possible to obtain 
ENSPC from aganglionic HSCR gut as well as determining the source of these cells. This 
can be further broken down into the aims of each results chapter: 
1. To determine which culture media is optimal for culturing human enteric 
neurospheres in terms of neurosphere yield and ENSPC yield. This work is 
required as the group has previously used two different types of media which 
are both capable of culturing neurospheres. There has however been no 
formal work to determine which media is best suited for this duty. 
2. To determine whether ENSPC are located within the thickened nerve trunks in 
aganglionic HSCR gut. This is a possible source of ENSPC and therefore these 
trunks should be investigated further. 
3. To determine whether ENSPC from aganglionic HSCR gut are of neural crest 
origin. If this can be determined then it will be possible to rule out a non neural 
source of ENSPC such as interstitial cells of Cajal which may have the ability to 
reprogram and act as ENSPC. 
4. To understand the structure and cell types associated with thickened nerve 
trunks within aganglionic HSCR gut compared to ganglia in ganglionic HSCR gut. 
This is required to determine which cell types within thickened nerve trunks 
may be the source of ENSPC in aganglionic HSCR gut. 
 
 
 Chapter 2 – Comparison of neurosphere development 
in different culture media 
2.1 Overview 
Our group has used two different media to culture neurospheres from ganglionic 
and aganglionic HSCR gut samples. However, there have been no formal 
experiments to determine which medium is optimal. It was found in this chapter 
that both media give rise to a similar number of ENSPC, however the horse serum 
based medium favoured the formation of neurospheres. Therefore, only horse 
serum medium will be used to culture neurospheres from human gut in subsequent 
experiments. This information will facilitate progress towards future neurosphere 
preparation for implantation into the gut of HSCR patients.  
 
 
 
 
 
 
 
 
 2.2 Introduction 
Previous neurosphere culture by our group has relied on a relatively complex 
medium known as neurosphere medium. The contents of this are detailed in the 
methods section of this chapter although to note this contains epidermal growth 
factor, fibroblast growth factor and fetal bovine serum. This medium, used together 
with non adherent conditions was successful at culturing neurospheres containing 
ENSPC and their enteric neurons and glia progeny.(Almond et al. 2007; Lindley et al. 
2008; Lindley et al. 2009) Alongside the work with neurospheres, cells from 
aganglionic gut were also cultured with the aim of growing smooth muscle cells to 
produce artificial sphincters for neurosphere implantation to test for restoration of 
function. These cells were grown in medium without added growth factors but 
containing horse serum rather than fetal bovine serum and using adherent dishes. 
Remarkably, in this horse serum medium neurospheres developed in cultures of 
aganglionic HSCR gut as discussed in Chapter 1. The subsequent experiments to 
compare the characteristics of neurospheres from ganglionic and aganglionic HSCR 
gut also used the horse serum medium however no formal experiments took place 
to determine whether there was any difference between horse serum medium and 
neurosphere medium in their abilities to culture neurospheres from cells isolated 
from human gut. 
 
 
 
 2.3 Aims 
We wanted to determine whether there was a difference between neurosphere 
yield, the proportion of ENSPC to other cells and also neuronal development in 
cultures using either the horse serum medium or neurosphere medium. This will 
achieved by culturing cells from the same patients in the two different media and 
performing immunocytochemistry staining with NCC and neuronal markers at four 
different time points.  
  
 2.4 Methods 
2.4.1 Buffers and media 
2.4.1.1 Horse serum medium 
DMEM high glucose (4.5% w/v) was supplemented with 20% v/v medium 199 
(Gibco®), 7% v/v heat inactivated horse serum (Gibco®), 100 Units/ml penicillin and 
100 μg/ml streptomycin. 
 
2.4.1.2 Neurosphere medium 
DMEM low (1% w/v) glucose (Gibco®, Life Technologies, Paisley, UK) was 
supplemented with 2% v/v chicken embryo extract (Sera Laboratories, West Sussex, 
UK), 1% v/v fetal calf serum (Sigma-Aldrich, Dorset, UK), 2mM final concentration L-
glutamine (Gibco®), 100 Units/ml penicillin, 100 μg/ml streptomycin, 0.05mM final 
concentration mercaptoethanol (Gibco®), 20ng/ml final concentration fibroblast 
growth factor II (Source Bioscience, Nottinghamshire, UK) and 20ng/ml final 
concentration epidermal growth factor (Sigma-Aldrich). 
 
2.4.1.3 Immunofluorescence Blocking Buffer  
PBS (CaCl2 / MgCl2 free, Gibco®) was supplemented with 20% v/v Goat serum 
(Gibco®), 0.1% w/v NaN3 (Sigma-Aldrich) and 1% w/v bovine serum albumin (Sigma-
Aldrich). 
 2.4.2 Cell isolation, culture and immunofluorescence  
2.4.2.1 Post natal human samples  
Ethical approval from North West 3 Research Ethics Committee (Ref:10/H1002/77) 
was obtained to remove 1cm2 of gut from paediatric patients undergoing stoma 
closure. The author obtained consent himself for the majority of samples from the 
patients’ parents and senior surgeons obtained consent where the author was not 
available. Parents were provided with information leaflets about the research which 
were individualised to those with HSCR and then those without HSCR (Appendix 1). 
The sample was transported under sterile conditions, wrapped in saline soaked 
gauze, to the universities stem cell laboratory at room temperature.  
 
2.4.2.2 Details of samples used 
Breakdown of samples  
Patient ID Pathology Age at operation Gestation at birth  
C011 Necrotising enterocolitis 2 months 32 weeks 
C012 Anorectal malformation 9 months 38 weeks 
C013 Necrotising enterocolitis 11 months 40 weeks  
C014 Anorectal malformation 10 months 34 weeks 
Table 2.1. Details of samples used in experiments in this chapter 
 
 
 
 2.4.2.3 Isolation of cells 
The sample was removed from the saline gauze and washed twice in 10ml PBS 
under sterile conditions in a 90mm petri dish (Sterilin, Newport, UK). A final wash of 
PBS supplemented with Gentamycin at a concentration of 50 µg/ml took place. A 
dissecting microscope (M165FC, Leica Microsystems, Bucks, UK) was then used to 
separate the mucosa and sub mucosa from the specimen along with removal of any 
blood vessels and any adipose tissue from the serosal surface (Diagram 2.2). The 
remaining tissue, which is the muscular layers, was then manually chopped into 
1mm2 pieces and transferred to a 15ml centrifuge tube (E1415-0200, Starlab, 
Hertfordshire, UK). The sample was centrifuged at 150g for 5 minutes in order to 
remove the PBS/Gentamycin solution. 2ml of Dispase (Gibco®) and 2ml of 
Collagenase IV (Gibco®), both at a concentration of 1% (w/v), were added to the 
sample and left in a water bath for 1 hour at 37oC. Every 15 minutes the sample was 
gently triturated using a 5ml glass pipette. After 1 hour the sample is centrifuged at 
150g for 5 minutes and fresh enzymes were added. This cycle would be repeated 2-
3 times depending on the appearance of the sample when 10µl was taken and 
viewed under an inverted microscope, (Nikon TMS-F, Nikon UK, Surrey, UK). Once 
there are no visible pieces remaining, centrifugation produced a pellet of cells which 
was re-suspended in PBS and passed through a 100µm cell strainer (Falcon®, BD 
Biosciences, UK). Following centrifugation a final pellet was re-suspended in Horse 
serum medium. 10µl of the sample was then taken and added to 10µl 0.4% (w/v) 
Trypan blue, before counting cells using a haemocytometer. Between 2-4 x 107 cells 
were then plated on 60mm adherent dishes (Nalge Nunc, New York, USA) with 6ml 
 of Horse serum medium or Neurosphere medium supplemented with 0.5µg/ml 
amphotericin B (Fungizone®, Gibco®) and 50µg/ml Gentamicin (Gibco®). The 
cultures were kept in an incubator at 37oC with 5% CO2 added to air.  
 
 
Diagram 2.2. Structure of gut tissue. The ganglia of the ENS are shown as green 
circles located in the submucosal plexus and the myenteric plexus. Nerve fibres 
connect ganglia within each layer, connect to ganglia in the other layer, innervate 
the circular and longitudinal muscle layers and innervate the mucosal layer. Blood 
vessels are depicted as red circles in the serosal layer. The layers marked in grey on 
the right of the diagram are dissected and discarded from human samples and the 
layers marked in green are kept and dissociated for tissue culture in this thesis. 
Adapted from Gulbransen and Sharkley 2012. 
 
 
 
 2.4.2.4 Refreshing culture media  
Twice a week the cultures were removed from the incubator in order to refresh the 
media. Firstly, the dish was swirled to move any debris into the centre of the dish, 
3ml of media was then removed from the sides of the dish using a 1ml pipette. This 
media was then replaced with 3ml of fresh media at 37oC. Amphotericin B and 
Gentamycin, in the concentrations above, were added to the media when feeding 
occurred during the first 7 days. 
 
2.4.2.5 Immunofluorescence of cells in culture using chamber well slides 
At isolation, before a cell suspension has been cultured, the volume of the 
suspension to contain 20,000 cells, was calculated. Alternatively, cells in culture had 
their supernatant removed by centrifugation at 150g for 5 minutes in a 15ml 
centrifuge tube. The pellet produced was then re-suspended in 1ml of 0.05% (w/v) 
Trypsin (Sigma-Aldrich) and added to the culture dish along with a further 2ml of 
Trypsin. After 10 minutes at 37oC in an incubator gentle manual dissociation 
occurred using a 1ml pipette. The suspension was then centrifuged to produce a 
pellet which was then re-suspended in 1ml of media. A cell count took place and the 
volume needed to give 20,000 cells was calculated. The remaining cells were re-
cultured on a fresh 60mm adherent dish. 
 
200µl of PBS containing 5% (v/v) Fibronectin (Merck Millipore) was added to each 
chamber of the adherent chamber well slide (Thermo Scientific). This was then 
 incubated at 37oC for 1 hour before the PBS containing Fibronectin was removed 
and a brief PBS wash took place. 20,000 cells were then re-suspended in 500µl of 
the same medium as they were in when in culture and added to each well. The cells 
were then incubated overnight at 37oC with 5% CO2. The following day a PBS wash 
took place and 200µl of 4% (w/v) paraformaldehyde was added to each well to fix 
the cells. Following a PBS wash, 200µl of immunofluorescence blocking buffer (IBB) 
was added to each well and left for 1 hour. Primary antibodies were then diluted in 
IBB to a concentration specified in table 2.3 and added to each well. At least one 
well for a control received IBB alone. The slide was then left overnight refrigerated 
at 2-4oC. A PBS wash took place and secondary antibodies also diluted in IBB then 
added to the concentration specified in table 2.4. The slide was then left at room 
temperature in the dark for 1 hour. A final PBS wash took place and the chamber 
was separated from the glass slide using the tool supplied with the chamber well 
slides. The slide was left until dry and a drop of ProLong® Gold antifade reagent 
with DAPI (Life Technologies) was placed over each well on the slide before covering 
with a cover slip (Thermo scientific). The slide was then left at room temperature in 
the dark overnight to dry before viewing and imaging.  
 
 
 
 
 
 2.4.2.6 Primary antibodies 
Primary antibodies 
Antibody  Supplier Concentration Host 
P75 (ab3125) Abcam 1:1000 Mouse Monoclonal IgG1 
NOS Abcam 1:200 Rabbit Polyclonal IgG 
Tuj (MMS-435P) Convance 1:500 Mouse Monoclonal IgG2a 
Table 2.3. Primary antibodies used in experiments in this chapter 
 
P75 was used as a neural crest marker as this binds to nerve growth factor 
receptors on neural crest cells and their differentiated progeny. This will therefore 
identify ENSPC, enteric neurons and glial in the cells obtained from human gut. This 
has been used previously by our group and others and dual stains with both 
neuronal and glial markers. (Almond et al. 2007; Lindley et al. 2009)  
 
2.4.2.7 Secondary antibodies 
Secondary antibodies 
Antibody  Supplier Concentration Host 
Alexa Fluor 488 - Anti-mouse Life Technologies 1:1000 Goat IgG 
Alexa Fluor 594 - Anti-rabbit Life Technologies 1:1000 Goat IgG 
Table 2.4. Secondary antibodies used in experiments in this chapter 
 
 
 
 2.4.2.8 Immunofluorescence of neurosphere sections 
Neurospheres were removed from culture and placed in a Peel-A-Way® mould 
(Polysciences Europe, Eppelheim, Germany). The neurospheres were then washed 
using PBS and fixed using 4% (w/v) paraformaldehyde for 15 minutes. The 
neurospheres are then embedded in 500µl of Shandon Cryomatrix (Thermo 
Scientific) and frozen to -80oC. After a minimum of 3 hours at -80oC sections were 
cut at 7µm with a MX35 microtome blade and a HM505N cryostat (both Thermo 
Scientific). Sections were mounted onto Superfrost® Plus microscope slides (Thermo 
Scientific) and washed once with PBS. A hydrophobic PAP marker pen (DAKO, 
Cambridgeshire, UK) was then used to delineate the neurospheres from unused 
sections of the slide. IBB was then added as described in the immunofluorescence 
of cells in culture using chamber well slides section and the same protocol was used 
from this point on to produce neurosphere section slides. 
 
2.4.2.9 Analysis of immunofluorescence  
Slides were viewed using a Leica DM IRB Inverted microscope (Leica microsystems). 
Images were captured using Leica Application Suite V4.3 (Leica Microsystems). 
Manual random sampling of rows of cells occurred using the 20x objective and the 
number of fluorescing cells and nuclei identified by DAPI were counted. Each row 
contained between 100-300 cells and the mean of the three rows was taken to give 
a percentage of cells expressing the antigen in the sample. A limitation of this 
approach is that it is vulnerable to observer bias however this was favoured over 
 the use of computer imaging software due to the cost and complexity of these 
systems. Adobe Photoshop CS3 (Adobe Inc., California, USA) was used for merging 
images. 
 
2.4.2.10 Phase contrast images of cultures 
Images of cultures were obtained using a Leica DMRB Upright microscope with a 
Leica DFC420C camera and captured using Leica Application Suite V4.3. 
 
2.4.2.11 Statistical analysis 
GraphPad Prism version 5 (GraphPad Software Corporation, California, USA) was 
used to create graphs and perform statistical analyses. Two-way ANOVA was 
performed unless otherwise specified.  
  
 2.5 Results 
2.5.1 Morphology of cells in culture 
Cells were successfully isolated from all the samples from all four patients without 
HSCR undergoing stoma closure. Cells were photographed at days 15, 30 and 45 in 
culture in the two media (Figure 2.5).  
                     
Figure 2.5. Representative phase contrast images of human ENS and smooth 
muscle cells cultured in neurosphere medium or horse serum medium. A-C: cells in 
neurosphere medium;  D-F: cells in horse serum medium; A and D: after 15 days in 
culture;  B and E: after 30 days in culture; C and F after 45 days in culture. Arrows in 
A highlight neurite like processes. Scale bars represent 200µm. 
____________________________________________________________________ 
 It is evident in the neurosphere medium that the morphology of the cells in culture 
do not vary between each time point (Figure 2.5 A-C). In the horse serum medium, 
the size of the neurosphere like structures appears to increase along with the 
number of them as time in culture increases (Figure 2.5 D-F). This is consistent with 
previous work completed by our group.(Almond et al. 2007)  
 
There are obvious differences between the morphologies of the cells in the 
neurosphere medium compared to the horse serum media. In the neurosphere 
medium, cells are flat and elongated or spindle-shaped and there are also some 
neurite like processes present in the culture (see arrows in Figure 2.5 A). However, 
in the horse serum medium there are neurosphere like structures that have budded 
off from the flat cells on the surface of the dish. Initially they are attached to the flat 
cells on the surface of the dish (Figure 2.5 D) but then detach and are suspended in 
the medium (Figure 2.5 F). It should also be noted that the numbers of cells visible 
on the surface of the dish decreases as the number of neurospheres increases.  
 
 
 
 
 
 
 2.5.2 P75 expression by cells in both media  
 
Figure 2.6. Representative immunocytochemistry images of human ENS and 
smooth muscle cells cultured in neurosphere medium or horse serum medium 
labelled with the neural crest cell marker P75. Cell nuclei are labelled blue with 
DAPI and P75 cell surface receptors are labelled green. A-D: cells in neurosphere 
medium; E-H: cells in horse serum medium; A and E: after overnight culture; B and 
F: after 15 days in culture; C and G: after 30 days in culture; D and H: after 45 days 
in culture. Scale bars represent 50µm. 
 After overnight culture cells expressing P75 within the isolated cells have not 
formed neurosphere like structures or elongated cells bearing the morphology of 
neurons (Figure 2.6 A and E). The cells cultured in the neurosphere medium 
expressing P75 are flat with long neurite projections to other expressing cells 
(Figure 2.6 B-D). After 45 days in neurosphere medium the cells appear more 
concentrated despite being seeded in equal number on the chamber slide, the cells 
expressing P75 have not formed neurospheres and long neurites are visible (Figure 
2.6 D). The cells in horse serum media have formed dense clusters containing cells 
expressing P75, these appear to be early neurospheres (Figure 2.6 E-G).  
 
 
 
 
 
 
 
 
 
 
 
 2.5.3 Percentage of cells expressing P75 in culture in both media 
             
Figure 2.7. Time course of expression of the neural crest marker P75. There is a 
significant difference (P<0.0001) in percentage positivity between number of days 
in culture however there is no significant difference (P=0.470) between the two 
media. Error bars represent standard error of mean (SEM), n=4. A two-way ANOVA 
was performed.  
 
There is no significant difference in the number of cells expressing P75 between the 
two media (Figure 2.7). Both conditions appear to promote culture of neural crest 
derived cells as the expression of P75 increases over time.  
 
 2.5.4 Number of cells present in culture at different time points 
      
Figure 2.8. Percentage change in total cell numbers in culture between passages. 
Each passage occurred every 15 days. Note a percentage change is shown rather 
than total numbers as the initial number of cells dissociated varies substantially. 
There is a significant difference (P <0.0001) in the change in total number of cells in 
culture over time however there is no significant difference (P=0.275) between the 
two media. Error bars represent SEM, n=4. A two-way ANOVA was performed. 
 
 
The change in number of cells since the last passage was calculated instead of total 
numbers as there was large variation in the number of cells isolated mainly due to 
the quality of sample obtained. Note the day 30 data relates to the change from day 
15. Data for the change in numbers between day 30 and day 45 have not been 
included as unfortunately culture contamination meant that some of the cultures 
 were discarded. During the first 15 days in culture there is a similar reduction in the 
number of living cells present in the two culture conditions however between day 
15 and day 30 there was a mean increase in the number of cells present in both 
media (Figure 2.8). There is a moderately large SEM however there is no statistical 
significance between the two media. Combined with the data on percentage of cells 
expressing P75 (Figure 2.7) this shows that the mean number of these cells present 
is similar in each culture.  
 
2.5.5 P75 expression within neurospheres in horse serum medium 
        
Figure 2.9. Immunohistochemistry of a representative section of a neurosphere 
removed from horse serum media culture stained with the NCC marker P75. Cell 
nuclei are labelled blue with DAPI and P75 cell surface receptors are labelled green. 
Arrows highlight neurite like processes. Scale bar represents 100µm.  
 The neurosphere like structures seen in horse serum media are neurospheres as 
they are shown to contain cells which label with P75 which has been previously 
shown to identify ENSPC and their neuronal and glial progeny (Figure 2.9). There are 
fine neurite processes present emerging from the periphery of the neurosphere and 
also within the neurosphere too (see arrows in Figure 2.9).  
 
2.5.6 ENSPC differentiation in both media 
 
Figure 2.10. Representative immunocytochemistry images of human ENS and 
smooth muscle cells cultured for 45 days in neurosphere medium or horse serum 
medium labelled with the immature and mature neuronal markers Tuj and NOS 
respectively. Cell nuclei are labelled blue with DAPI, cells expressing Tuj are green 
and cells expressing NOS are red. A: neurosphere medium; B horse serum medium. 
Scale bars represent 50µm. 
 
Although previous experience by our group with P75 has shown that the majority of 
cells dual label with P75 and neuronal markers after time in culture, it is not clear so 
far in these experiments whether cells in both conditions were differentiating as 
well as proliferating. Therefore neuronal markers were also used to look for the 
 presence of neurons in the samples. Neuronal cells in neurosphere medium appear 
elongated and fine neurites are visible (Figure 2.10 A) whereas neuronal cells in 
horse serum medium are clustered into what appears to be an early neurosphere 
(Figure 2.10 B). Most importantly in both media, there are not only immature 
neurons labelled with Tuj but also mature neurons labelled with NOS.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.6 Discussion 
In the literature, ENS and other neurospheres have mainly been derived and 
cultured under non adherent condition.(Almond et al. 2007; Lindley et al. 2008; 
Reynolds & Weiss 1992) However, it has been reported that a greater yield of 
neurospheres can be achieved using adherent culture dishes in CNS 
neurospheres.(Konagaya et al. 2011, 2013) As the use of autologous neurospheres 
as a therapy for HSCR is being explored, adherent culture conditions have been 
favoured by our group over recent years.(Wilkinson, Edgar & Kenny 2012) 
Additionally, an advantage of using adherent conditions is that there is no need to 
repeatedly passage neurospheres to prevent them adhering to the dish surface 
which has been required in previous work by our group. (Almond et al. 2007) The 
work in this chapter has therefore sought the optimal medium to culture ENS 
neurospheres under adherent conditions by comparing the two media previously 
used by our group.  
 
2.6.1 Both media produce a similar number of ENSPC 
It is clear from the mean percentage of P75 expression and the mean number of 
cells in both culture conditions at different time points that each medium produces 
a similar proportion and total number of neural crest derived cells. It has been well 
documented that ENS neurons and glia both express the NCC marker P75, 
consistent with the notion that this NCC marker also identifies ENSPC.(Joseph et al. 
2011; Lindley et al. 2009) Here it is evident that both media promote differentiation 
 of ENSPC into neurons which is an essential property of any medium to culture cells 
for autologous stem cell therapies in HSCR.(Wilkinson, Edgar & Kenny 2012) 
Therefore, in terms of culture of ENSPC it would seem that there is no difference 
between the two media. 
 
2.6.2 Horse serum medium promotes neurosphere formation 
The main difference between the two media is the morphology of the cells cultured 
in them. After 12 hours in culture the appearance of cells expressing P75 is similar 
suggesting that either these cells are yet to recover from the stresses of tissue 
dissociation or these cells are ENSPC prior to differentiation. Following 15 days in 
culture it is clear that horse serum medium promotes the formation of 
neurospheres containing ENSPC whereas neurosphere medium results in a flat 
appearance of the cells with long neurite projections. These findings sound 
paradoxical as neurosphere medium does optimally promote neurosphere 
development, however our work has used adherent conditions as opposed to non 
adherent conditions where neurosphere generation has been successful.(Almond et 
al. 2007; Lindley et al. 2009) As mentioned, there is evidence for the use of 
adherent conditions to generate neurospheres but in order to confirm these 
findings with ENS neurospheres further study could compare the two media under 
adherent and non adherent conditions.(Konagaya et al. 2011, 2013) 
 
 In the horse serum medium where neurospheres formed, phase contrast imaging 
showed that neurospheres began to form on the surface of the dish before 
enlarging in size and finally budding off to become suspended in the medium. This 
raises the question of whether one single ENSPC proliferates to form the 
neurosphere or if multiple cells adhere to form the structure together. Some study 
has already taken place to answer this question which found that ENS neurospheres 
are multipotent but this doesn’t address whether all neural crest derived cells in a 
neurosphere originate from one ENSPC.(Almond et al. 2007) In order to understand 
the formation of ENS neurospheres further work should look at these neurospheres 
forming possibly by utilising live cell imaging with immunofluorescence of ENSPC 
with P75 antibodies. It was also noticed that neurospheres were greater in size after 
a longer time in horse serum medium cultures, this would suggest that more cells 
are present however it is not clear as to whether there is any advantage in having 
larger neurospheres when considering autologous implantation. It is logical that an 
increased number of cells will have greater potential in the number of ENS neurons 
and ganglia that are formed however as a neurosphere becomes larger questions 
are raised about the ability of oxygen and nutrients to diffuse to the centre of these 
structures. If diffusion is not possible past a certain size then it is possible that 
central cells apoptose leaving a hollow structure. 
 
2.6.3 Presence of non neural crest derived cells within neurospheres 
In both media it is clear that there are non neural crest derived cells present. The 
majority of these cells in primary ENS neurospheres have been shown to be smooth 
 muscle cells in previous work from our group.(Wilkinson et al. 2013) The ratio of 
neural crest derived cells to smooth muscle cells increases from generation to 
generation of neurosphere because the culture conditions favour cells of the neural 
crest lineage.(Lindley et al. 2009) It is not clear however whether smooth muscle 
cells apoptose or neural crest derived cells proliferate at a much greater rate than 
other cells. It is also unknown what role, if any, these smooth muscle cells have 
within the ENS neurosphere. A clonal NCC can proliferate and differentiate into cells 
expressing smooth muscle actin as well as cells expressing neuronal markers, which 
may explain the origin of smooth muscles cells in ENS neurospheres.(Morrison et al. 
2000) A possibility for future work would be to attempt to culture purified 
neurospheres as it would be safer to implant one cell type instead of many. 
 
2.6.4 Further optimisation of media 
The major differences in the horse serum medium is the larger amount of serum 
and glucose present however it is not clear why this promotes the formation of 
neurospheres. It is clear that the components of the neurosphere medium are 
effective at culturing ENSPC. The question has to be asked as to whether some of 
these components should be added to the horse serum medium. However to 
undertake experiments to determine whether there is an advantage to developing a 
new medium a large number of cells and time will be required as many components 
at multiple concentrations will have to be tried.  
 
 It should also be noted that neurosphere medium has more components meaning 
that it is more expensive and leaves more room for variability between batches 
depending on where the components have been sourced from and when, which is 
another reason why horse serum medium is favourable. Before human implantation 
of ENS neurospheres can take place a serum free medium will have to be developed 
due to cross species infection risk which represents a challenge for the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2.7 Conclusion 
It is clear that horse serum medium with adherent conditions should be used for all 
future work involving the culture of human ENS neurospheres before human trials. 
There may be some advantage in adding components such as growth factors to the 
horse serum medium to create a new medium however these are areas for future 
work and are outside of the work achievable in this thesis. It must also be 
considered that there are advantages to using a simpler medium which will be 
easier to adapt to serum free, as there is hope that this work will culminate in 
clinical trials in the future. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 3 – Thickened nerve trunks as a source of 
ENSPC in aganglionic HSCR gut 
3.1 Overview 
This chapter confirms the previous observation that it is possible to isolate ENSPC 
from aganglionic short and long segment HSCR gut where there are thickened nerve 
trunks present. However it is demonstrated here that it is not possible to obtain 
ENSPC from aganglionic total colonic and total intestinal HSCR gut in which there 
are no thickened nerve trunks. The implication of this finding is discussed. 
 
 
 
 
 
 
 
 
 
 
 3.2 Introduction 
As described in chapter one, preliminary work from our group has shown that 
ENSPC can be isolated from aganglionic gut in short and long segment HSCR. These 
ENSPC then form mature neurons and ganglia of the ENS. There is however no data 
from patients with the rarer total colonic and total intestinal variants of HSCR. This 
information would be interesting as it is well documented that thickened nerve 
trunks are present within aganglionic gut in patients with short and long segment 
disease but these trunks are absent in total colonic and total intestinal 
disease.(Kobayashi, O'Briain & Puri 1994b; Solari, Piotrowska & Puri 2003). Thus, 
observations on aganglionic total colonic and total intestinal HSCR gut tissue may 
aid our identification of the source of ENSPC in aganglionic gut. Thickened nerve 
trunks are hypertrophied extrinsic nerves originating from the pelvic plexus. 
 
Normally, extrinsic nerve fibres consist of bundles of axons which are encased by 
Schwann cells. There are many of these bundles in nerves which are contained 
within fibrous layers, which are the endoneurium, epineurium and perineurium 
(Diagram 3.1). Immunohistochemistry of tissue sections of aganglionic HSCR gut 
using the NCC marker P75 by others and by our group have demonstrated high 
levels of immunoreactivity in cells at the periphery of the nerve fibre, which in a 
normal nerve would be the fibrous perineurium (Figure 3.2).(Kobayashi, O'Briain & 
Puri 1994b; Wilkinson et al. 2013)  
  
Diagram 3.1. Structure of a typical extrinsic nerve. The nerve is encased by the 
perineurium (P) consisting of perineurial cells. Axons (grey circles) are wrapped by 
myelinated Schwann cells (S) and non-myelinated Schwann cells (N). Within the 
endoneurium (E) are endoneurial fibroblasts (F). Adapted from Joseph et al 2004. 
 
 
Figure 3.2. Thickened nerve trunk expressing P75 in aganglionic short segment 
HSCR gut. The most intense expression is at the periphery of the nerve trunk but 
there is lower levels of expression within the trunk corresponding to the location of 
endoneurial compartments. Scale bar represents 50µm. 
 The hypothesis in this chapter is that the source of ENSPC obtained from 
aganglionic gut are the thickened nerve trunks. This is proposed as ENSPC in vitro 
express the NCC marker along with the thickened nerve trunks in vivo. As it is 
known that total colonic and total intestinal aganglionic gut do not have thickened 
nerve trunks observations on this tissue presents the possibility of testing this 
hypothesis.(Kobayashi, O'Briain & Puri 1994b; Solari, Piotrowska & Puri 2003) To 
this end, aganglionic gut samples were obtained from patients with different 
variants of HSCR, as confirmed by a consultant histopathologist, in order to attempt 
to isolate and culture ENSPC. The success or failure of this is then correlated with 
the presence or absence of thickened nerve trunks.  
 
3.3 Aim 
To establish whether thickened nerve trunks are the source of ENSPC expressing the 
NCC marker P75 in aganglionic HSCR gut. 
 
 
 
 
 
 3.4 Methods 
Cells from the muscular layers of aganglionic HSCR gut were dissociated and 
cultured with horse serum medium as described in chapter 2. It should be noted 
that samples from patients with total colonic and total intestinal disease were 
obtained at the site of stoma formation which was proximal jejunum in total 
intestinal disease and distal ileum in total colonic disease.  
 
3.4.1 Hospital histology reports 
Histology reports were produced by the Histopathology department at Alder Hey 
Children’s Hospital where the samples were obtained and accessed electronically. 
The presence or absence of thickened nerve trunks, along with the extent of 
disease, was noted. 
 
 
 
 
 
 
 
 3.4.2 Details of aganglionic samples used 
Breakdown of samples 
Patient ID Pathology 
H020 HSCR – total colonic 
H021 HSCR – short segment 
H022 HSCR – short segment 
H023 HSCR – short segment 
H024 HSCR – long segment 
H025 HSCR – total intestinal 
H027 HSCR – short segment 
H028 HSCR – short segment 
H029 HSCR – short segment 
H030 HSCR – short segment 
H031 HSCR – short segment 
H032 HSCR – short segment 
H033 HSCR – short segment 
H034 HSCR – short segment 
H035 HSCR – short segment 
Table 3.3. Details of samples used in experiments in this chapter 
 
Summary of samples obtained 
Pathology Number of samples 
HSCR – short segment 12 
HSCR – long segment 1 
HSCR – total colonic 1 
HSCR – total intestinal 1 
Table 3.4. Summary of samples used in experiments in this chapter 
 
 3.4.3 Immunofluorescence using chamber well slides 
This took place as described in section 2.4.2.5. The primary antibody used was P75 
(Abcam) and the secondary was Alexa Fluor goat anti-mouse 488 (Life Technologies) 
at the concentration specified in section 2.4.2.6 and 2.4.2.7. Negative controls 
consisting of immunocytochemistry with Alexa Fluor 488 secondary antibodies but 
no primary antibodies was performed for all samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.5 Results 
3.5.1 Histopathology reports on aganglionic samples obtained 
Histopathology reports found aganglionosis in all samples along with a presence or 
absence of thickened nerve trunks as detailed in table 3.5. Results from all levels of 
aganglionic biopsies was looked at to determine thickened nerve trunk presence. 
Pathology reports for samples used   
Patient ID Pathology Thickened nerve trunks? 
H020 HSCR – total colonic No 
H021 HSCR – short segment Yes 
H022 HSCR – short segment Yes 
H023 HSCR – short segment Yes 
H024 HSCR – long segment Few 
H025 HSCR – total intestinal No 
H027 HSCR – short segment Yes 
H028 HSCR – short segment Yes 
H029 HSCR – short segment Yes 
H030 HSCR – short segment Yes 
H031 HSCR – short segment Yes 
H032 HSCR – short segment Yes 
H033 HSCR – short segment Yes 
H034 HSCR – short segment Yes 
H035 HSCR – short segment Yes 
Table 3.5. Details of the extent of HSCR and presence of thickened nerve trunks in 
the aganglionic gut sample as determined by a consultant histopathologist for 
each patient 
 3.5.2 P75 expression by cells obtained from aganglionic HSCR gut after 
0.5 days in culture 
Cells were successfully obtained from all samples detailed above and 
immunocytochemistry was performed after overnight culture (Figure 3.6). In terms 
of cell yield, there was no difference between samples noticed.  
 
Figure 3.6. Phase contrast and immunocytochemistry of cells from aganglionic 
HSCR gut after overnight culture stained with P75 antibodies. A-C: short segment 
HSCR; D-F: total colonic HSCR; G-I: negative control consisting of short segment 
HSCR gut with only secondary antibodies. A, D, G: phase contrast; B, E, H: cell nuclei 
identified by DAPI (blue); C, F, I; neural crest derived cells expressing P75 (green). 
Scale bars represent 50µm. 
 
 Cells were present in both samples as shown by phase contrast imaging and 
identification of cell nuclei with DAPI (Figure 3.6 A and D, B and E). However P75 
positive neural crest derived cells were only present in aganglionic gut from short 
and long segment HSCR (Figure 3.6 C) but such cells were not detected from the 
samples from patients with total colonic or total intestinal HSCR (Figure 3.6 F). Also, 
the specificity of the secondary antibody is shown confirming the positive finding 
(Figure 3.6 I). The percentage of P75 expression and the number of samples tested 
in shown in Figure 3.8.  
 
 
 
 
 
 
 
 
 
 
 
 3.5.3 P75 expression by cells obtained from aganglionic HSCR gut after 
10 days in culture 
 
Figure 3.7. Phase contrast and immunocytochemistry of cells from aganglionic gut 
after 10 days in culture stained with P75 antibodies. A-C: short segment HSCR; D-F: 
total colonic HSCR; G-I: negative control consisting of short segment HSCR gut with 
only secondary antibodies. A, D, G: phase contrast; B, E, H: cell nuclei identified by 
DAPI (blue); C, F, I; neural crest derived cells expressing P75 (green). Scale bars 
represent 50µm. 
 
After 10 days culture the presence of cells was again confirmed with phase contrast 
imaging and identification of cell nuclei (Figure 3.7 A and D, B and E). Cells 
expressing P75 were only identified in aganglionic short and long segment HSCR gut 
 (Figure 3.7 C) and there was no expression of this marker detected amongst cells 
obtained from aganglionic total colonic or total intestinal HSCR gut (Figure 3.7 F). As 
at day 0, a negative control was performed which confirms the reliability of the 
method and the results (Figure 3.7 I). It should also be noted that the percentage of 
cells expressing P75 increased after time in culture, this is quantified in Figure 3.8. 
 
3.5.4 Percentage of P75 expression in aganglionic samples  
The percentage of cells expressing P75 for each variant of HSCR at each time point 
was calculated (Table 3.8). 
Mean P75 expression at day 0.5 and day 10 amongst the different extents of HSCR 
Pathology Number of 
patients 
Thickened 
nerve trunks?  
P75 
expression 
day 0.5 
P75 
expression 
day 10 
Short segment 12 Yes 10.0% +/- 1.9 
SEM 
22.7% +/- 2.9 
SEM 
Long segment 1 Few 11.1%  23.1%  
Total colonic 1 No 0% 0% 
Total intestinal 1 No 0% 0% 
 
Figure 3.8. Mean expression of P75, thickened nerve trunk presence and number 
of samples tested for each variant of HSCR within the aganglionic gut. The mean is 
shown along with the SEM for short segment samples. In the other variants of HSCR 
there is one sample of each so a mean cannot be calculated. 
 Figure 3.6, 3.7 and 3.8 show that it was possible to isolate and culture cells 
expressing P75 without fail from aganglionic short and long segment HSCR gut 
whereas it was not possible to do this from aganglionic total colonic or total 
intestinal HSCR gut. As well as observing this link the percentage of cells expressing 
P75 in culture from aganglionic short and long segment gut increased over time in 
keeping with previous work by the group.(Wilkinson et al. 2013)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 3.6 Discussion 
3.6.1 Aganglionic ENSPC are associated with thickened nerve trunks 
It was possible to identify P75 positive neural crest derived cells in the dissociates 
obtained from aganglionic gut in short and long segment HSCR where also 
thickened nerve trunks were present. However this was not achievable in samples 
from the 2 patients with total colonic and total intestinal HSCR where these 
thickened nerve trunks were absent. As our group has previously shown that 
mature enteric neurons and glia in vitro express P75, this fits with the hypothesis 
that the ENSPC which can be isolated from aganglionic gut in short and long 
segment disease are derived from the thickened nerve trunks.(Wilkinson et al. 
2013) The correlation between the presence of thickened nerve trunks in short and 
long segment HSCR and the absence of these in total colonic and total intestinal 
HSCR in our patients is consistent with reports from other groups.(Kobayashi, 
O'Briain & Puri 1994b; Solari, Piotrowska & Puri 2003) 
 
In the aganglionic gut obtained from the patient with long segment HSCR, few 
thickened nerve trunks were seen on histology. There is an obvious limitation with 
this classification which relies on the observations of the histopathologist and no 
quantitative evidence. However, in this sample a similar percentage of cells 
expressing P75 compared to aganglionic gut from short segment HSCR was 
observed at both time points. With only one patient it is not possible to draw a 
conclusion from this result and repeats with more samples are required. A method 
 of quantifying the number of thickened nerve trunks present should also be 
considered as this would allow the observation of a dose response relationship 
between the number of thickened nerve trunks and the percentage of P75 
expression in the tissue. This would ultimately strengthen the results in this chapter. 
 
3.6.2 P75 expression increases with time in culture 
It has also been shown in this experiment that if ENSPC were not identified in the 
single cell suspensions at isolation they are also not present after up to 10 days in 
culture. This may dismiss the possibility that when ENSPC are present in culture 
they are derived from non neural crest derived cells, such as reprogrammed 
mesenchymal cells, which are displaying a neural phenotype after time in 
culture.(Mareschi et al. 2006) It should also be noted that where cells expressing 
P75 were isolated, the percentage of cells expressing this marker increased after 10 
days in culture. This is likely due to the conditions used favouring the survival and 
proliferation of cells of NCC lineage whereas cells of non NCC lineage fail to survive 
in these conditions. This is in keeping with previous work by our group and is 
promising as it shows that when these cells are placed in the culture conditions 
used the percentage of these cells increases.(Almond et al. 2007; Lindley et al. 
2008; Lindley et al. 2009) This is important when considering the culture and 
implantation of human ENSPC into HSCR patients.(Wilkinson, Edgar & Kenny 2012) 
 
 
 3.6.3 Limitations 
The limitation of this work is that there was only one sample from each of the total 
colonic and total intestinal variants of HSCR which was investigated. This problem 
comes with any work looking at very rare disease and in the paediatric centre where 
our samples are obtained around one case of this disease is seen per year. Future 
work should therefore aim to repeat this work to confirm these findings. One way 
to increase the availability of these rare samples would be to create a national 
network where consent was applicable nationwide and human samples could be 
obtained.  
 
A further limitation of this study is that the site the aganglionic sample is taken from 
differs between patients depending on the extent of disease. There is little known 
about differences between proximal and distal aganglionic gut in total colonic and 
total intestinal patients. However, biopsies were obtained from multiple levels of 
the gut in these patients including the rectum which was reported in both cases as 
aganglionic with absent thickened nerve trunks. 
  
3.6.4 Aganglionic short and long segment HSCR gut can be used for 
stem cell retrieval 
Previously it was observed in six patients with short segment HSCR and one long 
segment HSCR that ENSPC were obtainable from the aganglionic gut.(Wilkinson et 
 al. 2013) This has now been repeated successfully with a further twelve short 
segment and one long segment aganglionic HSCR samples. This is consistent with 
work which found that ENSPC can arise from a niche external to the ENS ganglia.(Liu 
et al. 2009) This added evidence strengthens the possibility that autologous ENSPC 
implantation will be achievable using the aganglionic gut removed at operation for 
HSCR patients with short and long segment disease. This would of course allow any 
stem cell treatment to be much more practical and involve less cell number 
expansion before implantation compared to if ganglionic gut was required for 
ENSPC culture. Unfortunately in the rarer variants of disease ganglionic bowel will 
need to be sourced to obtain the progenitor cells. 
 
3.6.5 Revisiting the source of ENSPC obtainable from ganglionic HSCR 
gut 
If in aganglionic HSCR gut ENSPC are obtained from thickened nerve trunks it is not 
clear why ENSPC from ganglionic gut have similar characteristics as described 
previously.(Lindley et al. 2008; Lindley et al. 2009) This may be that the ENSPC are 
sourced from non-hypertrophied extrinsic nerves in ganglionic gut however the 
number of cells obtained from aganglionic gut should be greater than ganglionic 
gut, which is not the case. The similarities observed between ganglionic and 
aganglionic ENSPC may also lead towards glial including Schwann cells as a source of 
ENSPC as glia are present within ganglia of the ENS and Schwann cells are present 
 within extrinsic nerves.(Joseph et al. 2011; Kalcheim & Rohrer 2014; Laranjeira et al. 
2011) 
 
3.6.6 Revisiting the aetiology of HSCR 
The aetiology of HSCR is unknown however from small mammal studies it can be 
said that the most likely cause is failure of migration of ENCC.(Obermayr et al. 2013) 
If ENSPC that can be obtained from aganglionic HSCR gut are present within the 
thickened nerve trunks it seems more likely that ENCC have failed to migrate from 
the vagal neural crest to the distal gut. It is less likely that ENCC have migrated to 
the distal gut and failed to differentiate into enteric neurons and glia otherwise we 
should be able to obtain ENSPC from aganglionic gut where thickened nerve trunks 
are absent. However, this cannot be ruled out as there is work which shows that for 
sacral NCC to enter the hind gut extrinsic nerve fibres must be present.(Erickson et 
al. 2012) There is also the possibility that different variants of HSCR have different 
aetiologies which is suggested by the histopathological differences seen in the 
aganglionic tissue. 
 
3.6.7 ENSPC from aganglionic HSCR may be of Schwann cell lineage 
Cells of Schwann cell lineage are a possible source of ENSPC in aganglionic HSCR gut 
from within thickened nerve trunks. It has been put forward by two groups that 
ENSPC are most likely of glial origin when obtained from post natal gut and 
 Schwann cells are a type of glial cell in the peripheral nervous system.(Joseph et al. 
2011; Laranjeira et al. 2011) In addition it has also been possible to generate 
peripheral nervous system neurospheres from Schwann cells obtained for mouse 
and rat sciatic nerve.(Martin et al. 2012) Most significantly migrating NCC have been 
shown to dual label with SOX10 and PHOX2B showing that in the autonomic 
nervous system Schwann cells precursors also have the ability to undergo 
neurogenesis and hence have neuronal progenitor characteristics.(Kalcheim & 
Rohrer 2014) However, it has been shown that sacral NCC migrate into the hindgut 
with extrinsic nerve fibres so it is possible that ENSPC from aganglionic gut are NCC 
that have failed to differentiate and remain in progenitor form.(Erickson et al. 2012) 
This theory coincides with the finding that it is only possible to obtain ENSPC from 
aganglionic gut where thickened nerve trunks have formed. 
 
To fully explore the possibility of Schwann cells as a source of ENSPC further work 
should look at the characterisation of aganglionic HSCR tissue sections with a glial 
marker and expression of this marker should be looked for amongst cells isolated 
from aganglionic gut. The hypothesis would be that P75 positive cells co stain with a 
glial marker such as S100.(Hirose, Sano & Hizawa 1986) This could be evaluated 
using fluorescence activated cell sorting and is an area for further work. 
 
 
 
 3.6.8 The potential of a medical treatment for HSCR 
This work also raises the question as to why ENSPC fail to leave the thickened nerve 
trunks in vivo and develop into ganglia of the ENS. If this can be understood there is 
the possibility of therapeutic stimulation of these cells in vivo in HSCR patients to 
differentiate into a ENS and restore functionality in the aganglionic gut. This would 
treat HSCR without the need for surgical intervention which has substantial benefits 
for patients. 
 
3.7 Conclusion 
The work in this chapter has raised several key questions that should be a focus of 
further work. Most importantly the cell which is the source of ENSPC needs to be 
identified in order to develop an autologous stem cell transplant for HSCR patients 
which is as safe and efficacious as possible. Of equal importance the possibility of 
stimulating ENSPC in vivo to differentiate into a functional ENS should be explored 
to exclude the need of surgical intervention in these patients. 
 
 
 
 Chapter 4 – Are ENSPC obtained from aganglionic 
HSCR gut of neural crest lineage? 
4.1 Overview 
This chapter utilises fluorescence activated cell sorting (FACS) to show that neural 
crest derived cells obtained from aganglionic gut are the source of enteric neurons 
in vitro and are therefore ENSPC. This not only adds to our understanding of the 
origin of ENSPC that can be isolated from aganglionic HSCR gut but also raises 
questions on whether neural crest derived cells can be stimulated in situ to 
proliferate and differentiate into enteric neurons and glia in HSCR patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.2 Introduction 
It is clear from work by us and others that the thickened nerve trunks present in 
aganglionic HSCR gut contain cells of neural crest origin.(Kobayashi et al. 1994; 
Kobayashi, O'Briain & Puri 1994a; Wilkinson et al. 2013) Our group has shown that 
cells expressing markers for enteric neurons and glia cultured from aganglionic 
HSCR gut dual stain with the NCC marker, P75.(Wilkinson et al. 2013) Also, results in 
chapter 3 show that it was not possible to obtain ENSPC from aganglionic gut where 
thickened nerve trunks are absent and these results suggest that ENSPC are sourced 
from the thickened nerve trunks in aganglionic gut. Taking this into account, it is 
logical to assume that cells expressing the P75 NCC marker in culture are the same 
cells which label with P75 in the thickened nerve trunks within tissue sections in 
aganglionic gut, however there is a possibility that these cells derive from 
reprogramming of other isolated cells. These cells could be reprogrammed 
mesenchymal cells for example that behave as ENSPC in vitro.(Mareschi et al. 2006) 
Subsequently, there is evidence which shows that mature interstitial cells of Cajal 
have the ability to act as fibroblast like cell progenitors and therefore it must be 
considered whether they also have the capability to function as neural 
progenitors.(Huizinga & White 2008)  
 
In regards to a therapy for HSCR, it could be argued that it is irrelevant to know 
which cells are ENSPC as long as they are obtainable from aganglionic HSCR gut and 
differentiate into mature enteric neurons and glia. However, if more is understood 
 about the origin and characteristics of ENSPC it is more likely that it will be possible 
to understand how to control these cells in vivo post transplantation so that a 
functional ENS is generated without uncontrolled proliferation and tumour 
formation. Also, with further information about these cells, it is more likely that it 
will be possible to stimulate ENSPC in vivo to proliferate and differentiate in 
aganglionic gut without the need for stem cell retrieval. With this information, there 
is the possibility of developing a therapeutic treatment for HSCR and hence surgical 
intervention could be avoided. 
 
It is hypothesised that a sub-population of cells expressing the P75 NCC marker 
separated immediately from other cells dissociated from aganglionic gut in HSCR 
patients will differentiate in culture into enteric neurons. 
 
FACS has been used previously to sort cells obtained from rat sciatic nerve and 
normoganglionic embryonic mouse gut with the neural crest marker, P75, however 
to our knowledge this marker has not been used to sort human cells.(Bixby et al. 
2002) It is also unclear whether the sorted cells will survive the sorting process to 
be cultured when the duration between surgical resection of the sample to culture 
of the sorted cells is around 24 hours. Therefore, part of the results section details 
the development of the technique used.  
 
 4.3 Aims 
The first aim is to develop a technique that will allow FACS of freshly dissociated 
cells that will give two sub-populations of cells that can be cultured. Once this is 
achieved it can be used to determine whether ENSPC are primarily of neural crest 
lineage or not. 
 
 
 
 
 
 
 
 
 
 
 
 4.4 Methods 
4.4.1 Details of samples used (in chronological order) 
Breakdown of samples used 
Patient 
ID 
Pathology Ganglionic, Aganglionic or Both 
gut used  
H029 HSCR – short segment Aganglionic 
H026 HSCR – total colonic Ganglionic 
H030 HSCR – short segment  Both 
H030 HSCR – short segment  Both 
C015 Anorectal malformation Ganglionic 
C016 Anorectal malformation Ganglionic 
C017 Anorectal malformation Ganglionic 
C018 Anorectal malformation Ganglionic 
C016 Anorectal malformation Ganglionic 
H031 HSCR – short segment Both 
H032 HSCR – short segment Both 
C018 Anorectal malformation Both 
H033 HSCR – short segment Both 
H034 HSCR – short segment Both 
H035 HSCR – short segment Both 
 
Table 4.1. Details of samples used for experiments in this chapter. Gut samples 
from 15 patients were used in total. 9 of these patients had HSCR and 6 had 
anorectal malformations. Where applicable the innervation status of the samples 
used, as confirmed by a consultant histopathologist, is also specified. 
 
 
 4.4.2 Obtaining cultured cells 
To develop the labelling and sorting technique human gut cells which included 
ENSPC which had already been cultured for around 10 days were used. A pellet of 
cells was obtained using the technique for obtaining a cell pellet for 
immunocytochemistry in section 2.4.2.5 however 0.05% (w/v) Trypsin was replaced 
with 0.2% Collagenase IV (Gibco®) as P75 labelling and detection with FACS was 
unsuccessful when Trypsin was used. This is likely to Trypsin damaging the cell 
surface receptors. 
 
4.4.3 Tissue dissociation 
It was found that it was not possible to label and identify a separate subpopulation 
of NCC using the tissue dissociation technique used in other chapters of this thesis 
(section 2.4.2.3). This problem was likely due to the combination of the enzymes 
and time spent in the enzymes damaging or removing the P75 cell surface receptor 
from NCC. A technique published by another group was therefore modified and 
tested which allowed the identification of a sub-population of NCC after tissue 
dissociation.(Bixby et al. 2002) Thus the technique as described in section 2.4.2.3 
was modified as follows: 1% w/v Dispase was removed from the protocol leaving 1% 
w/v Collagenase IV as the only enzyme used. Tissue was left in the enzyme solution 
for 90 minutes with trituration through a 5ml pipette ten times every 15 minutes. 
This is a reduced duration compared to the original tissue dissociation method 
 where tissue was left in enzyme solution for between 2 and 3 hours depending on 
dissociation progress as assessed using an inverted microscope and a 10µl sample. 
 
4.4.4 Labelling of the NCC sub-population  
The cell suspension was transferred to ice-cold FACS buffer (PBS supplemented with 
1% w/v bovine serum albumin, penicillin (100units/ml) and 0.1% w/v streptomycin). 
After 20 min, 200,000 cell aliquots were re-suspended in 200µl FACS buffer 
containing 1:1000 mouse anti normal mouse IgG antibody (Santa Cruz) for the 
negative controls or 5 million cells in 1:1000 mouse anti-P75 antibody (Abcam) for 
FACS selection. After 30 minutes on ice, 800µl of ice-cold FACS buffer was added 
and cell aliquots were centrifuged and re-suspended in 200µl FACS buffer with 
1:1000 Alexa Fluor 488 goat anti-mouse secondary antibody (Life technologies). 
After 45 minutes on ice, 800µl of ice-cold FACS buffer was added and the cells were 
pelleted, re-suspended in 1ml FACS buffer and passed through a 70µm cell strainer.  
 
4.4.5 Immunocytochemistry 
The effectiveness of cell labelling was evaluated by also undertaking 
immunocytochemistry on 20,000 cells taken from the sample. The technique is as 
described in section 2.4.2.5 using P75 primary antibodies and Alexa Flour 488 
secondary antibodies where cells are cultured overnight before fixing. 
 
 4.4.6 Labelling of dead cells 
Where mentioned in the results section dual staining of cells for FACS took place 
with Sytox Orange (Life Technologies) dead cell stain. Following labelling of the NCC 
sub-population as detailed above 1µl of Sytox Orange was added to the labelled 
cells. The cells were left for 30 minutes before they were ready for FACS. 
 
4.4.7 Florescence activated cell analysis  
Florescence activated cell analysis took place using FACScalibur (BD Biosciences).  
 
4.4.8 Florescence activated cell sorting 
Fluorescence activated cell sorting took place using FACSaria (BD Biosciences). Cells 
were sorted into 5ml polystyrene round bottom tubes (BD Biosciences) that 
contained 1ml horse serum medium (DMEM high glucose (4.5% w/v) supplemented 
with 20% v/v medium 199 (Gibco®), 7% v/v heat inactivated horse serum (Gibco®), 
100 Units/ml penicillin and 100 μg/ml streptomycin). Filled tubes were then stored 
on ice until the sort had finished.  
 
 
 
 4.4.9 Culture of sorted cells 
Cells were initially cultured on adherent 24 well plates (Nalge Nunc, New York, USA) 
in densities of 100,000, 200,000 and 500,000 in horse serum medium. However the 
cells did not survive. 
 
Subsequently, 8 well chamber slides (Thermo Scientific) were prepared by coating 
with 10µg/cm2 Poly-D Lysine and 1µg/cm2 Laminin before washing in H2O and 
allowing to air dry. 100,000 cells from the P75 positive and negative sorted 
subpopulations were plated separately in each chamber in 500µl horse serum 
medium and incubated at 37°C with 5% CO2 for 6 days. Immunocytochemistry was 
performed as previously described with Tuj (Covance, Maidenhead, UK) antibodies 
diluted 1:500 in IBB. 
 
4.4.10 FACS software 
Flowing Software (Flowingsoftware.com) was used to count the number of events 
and produce graphs. 
 
 
 
 
 4.5 Results 
4.5.1 Overview of samples used to develop method and test 
hypothesis 
Patient 
ID 
Pathology FACS 
immediately 
post tissue 
dissociation? 
Ganglionic 
(G), 
Aganglionic 
(Ag) or 
Both (B) 
Successful 
FACS analysis 
with separate 
P75 
population? 
Successful 
sub-
population 
culture? 
H029 HSCR – short 
segment 
No Ag Yes Not 
attempted 
H026 HSCR – total 
colonic 
No G Yes Not 
attempted 
H030 HSCR – short 
segment  
Yes B No Not 
attempted 
H030 HSCR – short 
segment  
No B Yes No 
C015 Anorectal 
malformation 
Yes G Yes Not 
attempted 
C016 Anorectal 
malformation 
Yes G Yes Not 
attempted 
C017 Anorectal 
malformation 
Yes G Yes Not 
attempted 
C018 Anorectal 
malformation 
Yes G Yes Not 
attempted 
 Patient 
ID 
Pathology FACS 
immediately 
post tissue 
dissociation? 
Ganglionic 
(G), 
Aganglionic 
(Ag) or 
Both (B) 
Successful 
FACS analysis 
with separate 
P75 
population? 
Successful 
sub-
population 
culture? 
C016 Anorectal 
malformation 
No G Yes No 
H031 HSCR – short 
segment 
Yes B Yes No 
H032 HSCR – short 
segment 
Yes B Yes No 
C018 Anorectal 
malformation 
No B Yes No 
H033 HSCR – short 
segment 
Yes B Yes Yes 
H034 HSCR – short 
segment 
Yes B Yes Yes 
H035 HSCR – short 
segment 
Yes B Yes Yes 
 
Table 4.2. Table showing the results of experiments on each sample, underlining 
whether it was possible to identify a P75 positive population and whether it was 
possible to culture the sub-populations. Green rows indicate successful P75 
positive cell identification and culture of sub-populations. Amber rows indicate 
successful P75 positive cell identification without an attempt to culture the sub-
populations. Red rows indicate failure of P75 positive cell identification or failure of 
culture of sub-populations. 
 4.5.2 Identification of P75 expression amongst cells taken from culture 
using FACS 
Initially, cells which had been obtained from short segment aganglionic HSCR gut (as 
specified in Table 4.2) were taken after 10 days in culture and prepared for FACS 
then analysed (Figure 4.3).  
 
 
Figure 4.3. FACS analysis of cells cultured from short segment aganglionic HSCR 
gut labelled with P75. A: represents a dot plot showing the separate population of 
labelled cells. B: represents a overlaid histogram showing the separate population 
of labelled cells. The grey peak is the negative control using isotype primary 
antibodies and the clear peak is cells labelled with the P75 antibodies. The 
population of P75 labelled cells is 21.5% of the total cells present. 
 
It was possible to identify a population of cells labelled with the NCC marker P75 in 
previously cultured cells from short segment aganglionic HSCR gut (Figure 4.3 A and 
 B). The percentage of cells expressing P75 is consistent with the number identified 
using immunocytochemistry after the same duration in culture in chapter 3. 
 
4.5.3 Evaluation of the P75 antibody when used with FACS 
Following the results of the first experiment there was concern the positive finding 
could be dead cells binding to the P75 antibody due to changes in membrane 
permeability of dead cells which is well documented. Therefore to check that the 
P75 antibody was not binding to dead cells Sytox Orange dead cell stain was used 
with cultured cells.  
 
Figure 4.4. FACS analysis of cells cultured from total colonic ganglionic HSCR gut 
labelled with P75 and Sytox orange. A: represents a histogram showing cells 
labelled with P75. The red peak is the negative control using isotype primary 
antibodies and the clear peak is cells labelled with the P75 antibodies. The 
population of P75 labelled cells is 18.1% of the total cells present. B: represents a 
histogram showing cells labelled as dead with Sytox orange. The population of cells 
labelled as dead is 21.9% of the total cells present. C: represents a histogram of only 
cells labelled with P75 showing cells also labelled as dead with Sytox orange. The 
majority of cells are alive. 
 
 The vast majority of cells labelled with P75 were alive (Figure 4.4 C). This finding 
combined with the use an isotype primary antibody control is evidence that neural 
crest derived cells are being labelled specifically, and can be maintained alive for 
culture.  
 
4.5.4 Attempts to identify freshly dissociated cells expressing P75 
using FACS 
Identification of a P75 labelled population was then attempted on freshly 
dissociated cells from short segment aganglionic HSCR gut. The original tissue 
dissociation technique detailed in section 2.4.2.3 using 1% (w/v) Collagenase IV and 
1% (w/v) Dispase was used.  
 
Figure 4.5. FACS analysis of cells freshly dissociated from short segment 
aganglionic HSCR gut labelled with P75. A: represents a dot plot showing no 
separate population of labelled cells. B: represents a histogram showing no 
separate population of labelled cells. The grey peak is the negative control using 
isotype primary antibodies and the clear peak is cells exposed to P75 antibodies.  
 It was not possible to label and identify a population of cells expressing P75 in 
freshly dissociated cells (Figure 4.5 A and B). Immunocytochemistry was performed 
on a sample of the cells which did identify cells expressing P75 at a percentage 
consistent with findings in chapter 3 (not shown). 
 
4.5.5 Identification and sorting of freshly dissociated cells expressing 
P75 using FACS with culture and characterisation of sub-populations 
As this technique works with cultured cells it is likely that the effects of the 
dissociation process are preventing the P75 antibody binding to the cell surface 
receptors on neural crest derived cells. The tissue dissociation was therefore 
modified as described in the methods section in an attempt to retain the structure 
of the cell surface receptors and allow labelling of freshly dissociated cells. This 
technique was successful and sub-populations of cells were cultured and 
immunocytochemistry was performed to characterise the sub-populations. 
 
 
 
 
 
                         
Figure 4.6. Fluorescence activated cell sorting of cells obtained from ganglionic 
and aganglionic HSCR gut immediately after tissue dissociation and 
characterisation of each population following 6 days in culture. A and B: 
histograms of the FACS displaying P75 positive and negative selected 
subpopulations. The grey peaks are the negative control using isotype primary 
antibodies and the clear peak are cells labelled with the P75 antibodies. The arrow 
in B highlights a second peak of P75 expression. C and D: Tuj immunofluorescence 
staining of the P75 positive cell subpopulations from ganglionic and aganglionic 
bowel respectively after 6 days culture (note that the majority of cells are Tuj 
positive). E and F: Tuj immunofluorescence staining of the P75 negative cell 
subpopulations from ganglionic and aganglionic bowel respectively (note the 
absence of Tuj positive cells). 
 It was possible to label, identify and sort cells expressing P75 from cells freshly 
dissociated from ganglionic and aganglionic short segment HSCR gut (Figure 4.6 A 
and B). The histogram from aganglionic gut differs from ganglionic gut in the way 
that there is a second peak of cells expressing P75 in the aganglionic sample but not 
to such an intensity in terms of florescence as the majority of positively sorted cells 
which are identified on the histograms (Figure 4.6 A-B, see arrow for second peak 
on B).  
 
Initially, it was attempted to culture the two sub-populations of cells on adherent 
24 well plates as described in the methods section but neither population survived. 
It is thought that this was due to the limited cell population size as trophic factors 
secreted from cells would be much more dilute compared to culture conditions 
used previously. The failure of survival may also have been due to the trauma that 
the cells experienced in the 24 hour period between tissue dissociation and culture 
with this FACS method. Therefore, laminin and poly-d-lysine coated chamber slides 
were used (see methods) for culturing sorted cells. The positively sorted cells 
survived but there were fewer cells from the negatively sorted sub-population 
which survived in culture for 6 days. This is most likely due to the culture conditions 
favouring cells of neural crest lineage. In order to show this is the case and that the 
negative population is not just cell debris, this population was stained with the dead 
cell stain, Sytox orange, immediately after sorting (Figure 4.7). 
 
 In both the ganglionic and aganglionic HSCR gut the positively stained sub-
populations expressed the neuronal marker Tuj after 6 days in culture (Figure 4.6 C 
and D). The mean percentage of cells expressing Tuj are 89.3% and 85.4% (n=3) in 
ganglionic and aganglionic gut respectively. In both the ganglionic and aganglionic 
HSCR gut the negatively stained sub-populations did not express the neuronal 
marker Tuj after 6 days in culture (Figure 4.6 E and F). A negative control consisting 
of staining with only the secondary antibody was carried out for all sub-populations 
(not shown). 
 
 
Figure 4.7. FACS analysis of the P75 negative sub-population of cells immediately 
after sorting from freshly dissociated cells from short segment aganglionic HSCR 
gut labelled with Sytox orange, dead cell stain. A: represents a dot plot showing 
the separate population of cells labelled as dead. B: represents a histogram showing 
the separate population of cells labelled as dead. The grey peak represents a control 
consisting of unlabelled cells whereas the white peak represents cells labelled with 
the dead cell stain, Sytox orange. 5.6% of cells labelled as dead. 
 Of the cells sorted as not expressing P75 only 5.6% of the cells were dead 
immediately after sorting (Figure 4.7 A and B). Once the cells were seeded onto a 8 
well chamber slide for culture the majority of cells appeared dead and did not 
adhere to the slide hence the majority of cells fail to take to culture conditions. A 
much larger proportion of the cells in the P75 positive sub population survive in the 
culture conditions used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 4.6 Discussion 
4.6.1 ENSPC obtained from aganglionic HSCR gut are of neural crest 
lineage 
It has been shown that cells of neural crest lineage separated by FACS from other 
cells immediately after dissociation from aganglionic short segment HSCR gut can 
differentiate in vitro into neurons. This shows that P75 positive neural crest derived 
cells in aganglionic gut are partially or wholly responsible for ENSPC and the mature 
enteric neurons and glia which have been cultured from aganglionic short segment 
HSCR gut previously.(Wilkinson et al. 2013) Moreover, the fact that it was not 
possible to derive neurons from the population of cells not expressing P75 on 
isolation suggests that there is no non neural crest lineage source of cultured 
ENSPC.  
 
4.6.2 The source of ENSPC in ganglionic HSCR gut 
This finding questions the source of ENSPC which can be obtained from ganglionic 
HSCR gut. Previously it was thought that these cells are sourced from the ganglia, as 
this is the main source of neural cells in ganglionic gut.(Almond et al. 2007) 
However, now ENSPC have now been shown to be present in both ganglionic and 
aganglionic gut and also ENSPC cultured from each segment behave the same in 
vitro and upon implantation into ex vivo aganglionic mouse gut, it is entirely 
possible that ENSPC obtainable from ganglionic HSCR gut are extra-
 ganglionic.(Wilkinson et al. 2013) It is therefore feasible that cells expressing P75 
associated with the extrinsic nerves are the source of ENSPC in ganglionic HSCR gut. 
  
4.6.3 The cellular origin of ENSPC in HSCR gut 
As cells of non neural crest lineage did not give rise to neurons we can consider the 
cellular origins of ENSPC in HSCR gut. It is possible that cells of Schwann cell lineage 
are the source of ENSPC in aganglionic HSCR gut and either these cells of Schwann 
cell lineage, associated with extrinsic nerves or other glial cells associated with the 
ganglia, are the source in ganglionic HSCR gut. As discussed in chapter 3 it has been 
found that Schwann cell precursors have dual roles as functional Schwann cells and 
neuronal progenitors in the developing parasympathetic nervous system, which 
may also be the case in HSCR gut.(Kalcheim & Rohrer 2014) Subsequently, it is 
known that glial cells have a role in neurogenesis in vitro and also described by one 
group in vivo.(Joseph et al. 2011; Laranjeira et al. 2011) A possible non glial source 
of ENSPC are neuron cell bodies, which are present in ganglia but absent in extrinsic 
nerves which only contain the axon.(Topp & Boyd 2006) This seems less likely 
though due to common characteristics of ENSPC from ganglionic and aganglionic 
gut.(Wilkinson et al. 2013) The other well documented NCC derivative in extrinsic 
nerve trunks are fibroblasts within the endoneurium, however little is known about 
the ability of these cells to undergo neurogenesis.(Joseph et al. 2004) The migration 
of sacral NCC during development into the hindgut with extrinsic fibres has been 
described.(Erickson et al. 2012) This is another possibility as to a source of ENSPC in 
 aganglionic gut as NCC may be left in an un-differentiated state from development 
within the gut. 
 
To explore these possibilities further we could use the experience gained using FACS 
with human gut cells in this chapter. Small changes to the method could take place 
which allow separation of a population of cells expressing a glial marker, such as 
S100.(Hirose, Sano & Hizawa 1986) This would give an isolated sub-population of 
glial cells which could then be cultured and characterised in a similar way to 
experiments in this chapter to determine whether glial, and therefore Schwann 
cells, can behave as ENSPC.  
 
4.6.4 Differences in FACS histograms between ganglionic and 
aganglionic HSCR gut cells labelled with P75 
Most interestingly there is a key difference in the FACS histogram of cells obtained 
from ganglionic HSCR gut to aganglionic HSCR gut when labelled with P75. The 
second peak seen in the aganglionic sample shows that there are two populations 
of cells labelling with different intensities of fluorescence suggesting that two 
different types of neural crest cell are present. This is consistent with 
characterisation of ganglionic compared to aganglionic HSCR gut where there is 
intense expression of P75 in a ring surrounding thickened nerve trunks in 
aganglionic gut which is not present around ganglia.(Kobayashi, O'Briain & Puri 
1994b) It is therefore suggestive that the second peak seen in aganglionic gut with 
 FACS is from cells associated with the ring of intense P75 expression surrounding 
thickened nerve trunks on immunohistochemistry. Further characterisation of these 
nerve trunks is required however to confirm this finding. Further FACS could 
separate the two different peaks into independent sub-populations and the ability 
to differentiate into enteric neurons could then be tested. This would provide 
evidence for the cell type which are acting as ENSPC in aganglionic gut. Again the 
similarities between ENSPC from both ganglionic and aganglionic HSCR gut question 
whether the cells with increased expression do have a role.(Wilkinson et al. 2013) 
 
4.6.5 Implications of findings in this chapter 
This work has several implications. Firstly, it has been shown that neural crest 
derived cells are the source of ENSPC obtained from aganglionic HSCR gut. This will 
allow further work to explore how NCC can be stimulated to differentiate and 
proliferate into an ENS in vivo in HSCR patients. This information could be used to 
develop a therapeutic treatment for HSCR. This would be even more promising if 
the exact cell type could be established. Secondly, it should be established whether 
neurospheres can be cultured from isolated cells of neural crest origin and if so 
whether they have the same characteristics in terms of restoring contractility in ex 
vivo aganglionic mouse gut as un-purified enteric neurospheres. Now that a cell 
sorting technique has been developed this work could take place with the 
hypothesis that a purified neural crest cell neurosphere will be more effective in 
terms of restoring contractility as a neurosphere containing other cell types. Even, if 
this is not the case there are likely to be major safety advantages to transplanted 
 one lineage of cells by excluding other cells such as smooth muscle cells when 
considering a future stem cell therapy for HSCR.(Wilkinson, Edgar & Kenny 2012)  
 
Finally, the finding that neural crest derived cells alone are responsible for the 
ENSPC obtained from HSCR gut make it likely that in normal human development 
NCC are the only progenitor for the ENS. Although this has been shown in several 
mouse studies this adds further evidence to human ENS development and can be 
used to direct further work exploring the aetiology of HSCR.(Obermayr et al. 2013) 
 
 
 
 
 
 
 
 
 
 
 
 4.7 Conclusion 
This chapter has found that ENSPC are neural crest derived cells when obtained 
from both ganglionic and aganglionic HSCR gut. This adds understanding to the 
previous findings that ENSPC can be isolated from aganglionic HSCR gut and 
questions the source of ENSPC in ganglionic HSCR gut. This work raises several 
pertinent questions, but most importantly further work should look to identify the 
cell type which behaves as ENSPC in aganglionic HSCR gut. Currently it is felt that 
cells of Schwann cell lineage are responsible, however to develop a safe and 
efficacious stem cell therapy, along with the possibility of a therapeutic treatment 
for HSCR, this information needs to be known.  
 
 
 
 
 
 
 
 
 Chapter 5 – Characterisation of ganglionic and 
aganglionic HSCR gut 
5.1 Overview 
This chapter builds on previous work characterising aganglionic HSCR gut and in 
particular, the thickened nerve trunks. Full thickness gut was obtained from HSCR 
patients and labelled with antibody markers for NCC, neurons, glia and surrounding 
muscular tissue to detail the histology in both ganglionic and aganglionic HSCR gut. 
Findings in this chapter add understanding to work carried out in chapters 3 and 4 
in vitro where it was found that ENSPC from aganglionic gut are neural crest derived 
cells associated with the thickened nerve trunks.  
 
 
 
 
 
 
 
 
 
 5.2 Introduction 
As detailed in chapters 3 and 4 it has been shown that it is possible to isolate from 
short and long segment aganglionic HSCR gut ENSPC cells which express the neural 
crest maker P75. As cells in the thickened nerve trunks in the aganglionic gut also 
express P75, along with the association of not being able to obtain ENSPC from 
aganglionic gut where thickened nerve trunks are absent, it is hypothesised that 
these cells within the trunks have progenitor properties. In order to determine 
which cell has the progenitor properties of the cells present within the thickened 
nerve trunks, further characterisation is needed. 
 
Electron microscopy has previously been used to characterise thickened nerve 
trunks in aganglionic gut compared to intrinsic and extrinsic nerves in ganglionic 
gut.(Baumgarten, Holstein & Stelzner 1973) It was observed that Schwann cells, 
axons and large collagen filled spaces were contained within the endoneurium of 
these nerves. The Schwann cells seen in this study were of immature appearance, 
as the cytoplasm contained few organelles, compared to mature Schwann cells. It 
was also stated that the Schwann cells in thickened nerve trunks bear the 
appearance of un-differentiated Schwann cell precursors in the developing 
peripheral nervous system. In terms of the axons, there were more present per 
Schwann cell in the thickened nerve trunks compared to extrinsic nerves in 
ganglionic gut and the axons were hypertrophied as they contained large fluid filled 
vesicles. The presence of these is attributed to the fact that the axons are blind 
 ending and fail to synapse. Finally, it was reported that the thickened nerve trunks 
were encased abnormally in multiple layers of coherent perineurial cells.  
 
There has been some more recent work published characterising histopathologically 
aganglionic HSCR gut, however the majority of this work focuses on the finding of 
the thickened nerve trunks and their relation to other cells such as Interstitial cells 
of Cajal without focus on the internal structure of the trunks.(Matsuda et al. 2006; 
Nemeth et al. 2001; Solari, Piotrowska & Puri 2003) One study has reported the 
presence of a thick ring of cells surrounding the thickened nerve trunks which 
labelled with P75 antibodies, possibly consisting of perineurial cells.(Kobayashi, 
O'Briain & Puri 1994b) This study found a similar appearance in mesenteric nerves 
and therefore concluded that thickened nerve trunks in aganglionic gut are of 
extrinsic origin. This finding is consistent with previous work by our group in which 
this thick ring of cells expressing P75 was also detected.(Wilkinson et al. 2013) It is 
unclear why thickened nerve trunks are present in aganglionic gut and why they 
differ in appearance to normal extrinsic nerves. With antibody staining, paying 
particular attention to the varying intensities of P75 expression and associated 
neuronal plus glia expression it is hoped that more can be understood about the 
internal structures of these nerves but most importantly potential sources of ENSPC 
from aganglionic gut can be identified.  
 
 ENSPC obtained from ganglionic and aganglionic HSCR gut have similar 
characteristics, in that they differentiate into enteric neurons and glia in vitro and 
can restore contractility in aganglionic ex vivo mouse gut when transplanted, this 
therefore suggests that they are from the same source. It is hoped that by 
characterising ganglionic gut as well as aganglionic gut we can come closer to 
understanding the similarities that both groups of cells share. In order to do this, 
ganglia and extrinsic nerves in ganglionic gut must be compared to thickened nerve 
trunks within aganglionic gut. 
 
5.3 Aim 
The aim of the experiments in this chapter is to characterise using 
immunofluorescence both ganglionic and aganglionic HSCR gut focussing on the 
thickened nerve trunks. In order to do this a variety of markers associated with the 
thickened nerve trunks which identify neurons, glia and NCC will be used. The 
surrounding smooth muscle will also be identified to determine how this relates 
structurally to nerve fibres. 
 
 
 
 
 
 5.4 Methods 
5.4.1 Immunohistochemistry  
Human full thickness gut tissue was obtained as described in section 2.4.2.1. Tissue 
for immunohistochemistry was immersed in 4% (w/v) paraformaldehyde for 2-3 
hours to fix the tissue. The tissue was then rinsed twice with PBS and placed 
overnight in 20% (w/v) sucrose before dissection took place to orientate the tissue 
planes. Tissue was then placed in Peel-A-Way moulds (Polysciences Europe, 
Eppelheim, Germany), embedded in clear Shandon Cryomatrix (Thermo Scientific) 
and left at -80oC overnight. 7µm sections of tissue were then cut using a MX35 
microtome blade and HM505N cryostat (both Thermo Scientific) at -22oC. Tissue 
was mounted on Superfrost Plus microscope slides (Thermo Scientific) and stored at 
-80oC. 
 
Antibody staining, slide preparation and imaging then took place as described for 
immunocytochemistry in section 2.4.2.5. The antibodies used are described below. 
 
 
 
 
 
 5.4.2 Primary antibodies 
Primary antibodies  
Antibody  Supplier Concen
tration 
Host Target 
P75 (ab3125) Abcam 1:1000 Mouse 
Monoclonal 
IgG1 
NCC (Morrison et al. 
2000) 
Calretinin (ab702) Abcam  1:250 Rabbit 
Polyclonal IgG 
ENS cells (Lindley et 
al. 2009) 
S100 (ab868) Abcam 1:500 Rabbit 
Polyclonal IgG 
Glia (Almond et al. 
2007) 
Tyrosine 
Hydroxylase (ab112) 
Abcam 1:500 Rabbit 
Polyclonal IgG 
Early Dopaminergic 
neurons (Almond et 
al. 2007) 
Laminin (l9393)  Sigma-
Aldrich 
1:500 Rabbit 
Polyclonal IgG 
Connective tissue 
(Kostrominova, 
2011) 
SMA (ab7817) Abcam 1:200 Mouse 
Monoclonal 
IgG2a 
Smooth muscle 
(Lindley et al. 2009) 
Table 5.1. Primary antibodies used in experiments in this chapter 
 
5.4.3 Secondary antibodies 
Secondary antibodies 
Antibody  Supplier Concentration Host 
Alexa Fluor 488 - Anti-mouse Life Technologies 1:1000 Goat IgG 
Alexa Fluor 594 - Anti-rabbit Life Technologies 1:1000 Goat IgG 
Table 5.2. Secondary antibodies used in experiments in this chapter 
 5.5 Results 
5.5.1 Expression of P75 and calretinin in aganglionic HSCR gut 
 
Figure 5.3. Immunohistochemistry of full thickness aganglionic short segment 
HSCR gut labelled with P75 and Calretinin. A and B: longitudinal smooth muscle 
layer; C and D: extrinsic nerve fibres in the inter-muscular layers; E and F: circular 
smooth muscle layer; G and H: extrinsic nerve fibres in the submucosal layer. 
A,C,E,G are labelled with DAPI (blue) and P75 (green). B,D,F,H are labelled with 
Calretinin (red). Scale bars represent 50µm. 
 It is evident that there is a ring of cells expressing high levels of P75, surrounding a 
thickened nerve trunk with some expression from within the structure (Figure 5.3 
C). Within the muscular layers in aganglionic HSCR tissue there is some expression 
of P75 within neurite like structures (Figure 5.3 A and E). Calretinin staining, which 
identifies enteric neurons confirms the innervation status of the tissue (Figure 5.3 
B,D,F,H).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.5.2 Expression of P75 and calretinin in ganglionic HSCR gut 
  
Figure 5.4. Immunohistochemistry of full thickness ganglionic short segment HSCR 
gut labelled with P75 and Calretinin. A and B: full thickness gut; C and D: 
submucosal plexus; E and F: circular smooth muscle layer; G and H: myenteric 
plexus. A,C,E,G are labelled with DAPI (blue) and P75 (green). B,D,F,H are labelled 
with DAPI (blue) and Calretinin (red). Scale bars represent 50µm. 
 In ganglionic HSCR gut the ganglia express P75 however there is one intensity of 
expression throughout the ganglia and certainly no surrounding ring (Figure 5.4 C 
and G). Within the muscular layers there is some expression of P75 running in in the 
muscular fibres (Figure 5.4 A and G). Calretinin staining, which identifies enteric 
neurons confirms the innervation status of the tissue (Figure 5.4 B,D,F,H). 
Ganglionic HSCR gut was also compared to gut obtained from patients without 
HSCR, there was no differences observed between ganglia or nerve distribution (not 
shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.5.3 Expression of P75 and S100 in aganglionic HSCR gut 
 
Figure 5.5. Immunohistochemistry of full thickness aganglionic short segment 
HSCR gut labelled with P75 and S100. A-C: Longitudinal muscle layer; D-F: Inter-
muscular layer fibres; G-I: Circular muscle layer; J-L: Submucosal fibres; M-O: Blood 
vessel within submucosal layer. A,D,G,J,M: are labelled with DAPI (blue) and P75 
(green); B,E,H,K,N: are labelled with DAPI (blue) and S100 (red); C,F,I,L,O: are 
labelled with P75 (green) and S100 (red). Scale bars represent 50µm. 
                P75                                       S100                             P75 and S100 
 When aganglionic tissue was dual labelled with P75 and S100, a glial marker, it 
appears that the centre of thickened nerve trunks dual stain however the ring 
intensely expressing P75 does not express S100 (Figure 5.5 F and L). Many of the 
fibres expressing P75 in the muscular layers also express S100, showing that most of 
fibres are associated with glial cells (Figure 5.5 C and I). Finally, a blood vessel can 
be identified in the aganglionic gut showing the clear difference in appearance 
between this and the thickened nerve trunks (Figure 5.5 M-O). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.5.4 Expression of P75 and calretinin in ganglionic HSCR gut 
 
Figure 5.6. Immunohistochemistry of full thickness ganglionic short segment HSCR 
gut labelled with P75 and S100. A-C: Longitudinal muscle layer; D-F: Myenteric 
plexus; G-I: Circular muscle layer; J-L: Submucosal plexus. A,D,G,J: are labelled with 
DAPI (blue) and P75 (green); B,E,H,K: are labelled with DAPI (blue) and S100 (red); 
C,F,I,L: are labelled with P75 (green) and S100 (red). Arrow in L shows identifies an 
extrinsic nerve like fibre. Scale bars represent 50µm. 
 
 
                P75                                            S100                                 P75 and S100 
 When ganglia are dual stained with P75 and S100 there is expression of both 
markers throughout (Figure 5.6 F and L). Structures with the appearance of extrinsic 
nerves can also be identified in the ganglionic gut (Figure 5.6 L see arrow). Many of 
the fibres expressing P75 in the muscular layers also express S100, identifying the 
presence of glial cells (Figure 5.6 C and I). Ganglionic HSCR gut was also compared 
using the S100 glial marker to gut obtained from patients without HSCR, there were 
no differences observed (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.5.5 Expression of P75 and tyrosine hydroxylase in HSCR gut 
 
Figure 5.7. Immunohistochemistry of full thickness ganglionic and aganglionic 
short segment HSCR gut labelled with P75 and Tyrosine Hydroxylase. A-C: 
ganglionic gut; D-F: aganglionic gut. A,D: are labelled with DAPI (blue) and P75 
(green); B,E: are labelled with DAPI (blue) and TH (red); C,F: are labelled with P75 
(green) and TH (red). Scale bars represent 50µm. 
 
In ganglia the dopaminergic neuronal marker, tyrosine hydroxylase (TH), dual labels 
with P75 in a similar pattern to S100 in that there is expression of both markers 
throughout the ganglia (Figure 5.7 C). In contrast, when aganglionic tissue is dual 
stained, the centre of the thickened nerve trunks expresses both P75 and TH 
however the ring intensely expressing P75 does not label with TH (Figure 5.7 F). 
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 5.5.6 Expression of P75 and laminin in HSCR gut 
 
Figure 5.8. Immunohistochemistry of full thickness ganglionic and aganglionic 
short segment HSCR gut labelled with P75 and Laminin. A-C: ganglionic gut; D-F: 
aganglionic gut. A,D: are labelled with DAPI (blue) and P75 (green); B,E: are labelled 
with DAPI (blue) and Laminin (red); C,F: are labelled with P75 (green) and Laminin 
(red). Scale bars represent 50µm. 
 
Antibodies to laminin were used to identify the basement membranes associated 
with the nerve structures. In ganglionic gut there was no expression of this marker 
surrounding ganglia (Figure 5.8 C). However, when thickened nerve trunks were 
dual stained with P75 and laminin there was expression of both markers in close 
relationship to the ring surrounding the trunks. The laminin however was expressed 
very marginally externally to the P75 expression (Figure 5.8 F). 
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 5.5.7 Expression of smooth muscle actin and S100 in HSCR gut 
 
Figure 5.9. Immunohistochemistry of full thickness ganglionic and aganglionic 
short segment HSCR gut labelled with Smooth Muscle Actin and S100. A-C: 
ganglionic gut; D-F: aganglionic gut. A,D: are labelled with DAPI (blue) and SMA 
(green); B,E: are labelled with DAPI (blue) and S100 (red); C,F: are labelled with SMA 
(green) and S100 (red). Scale bars represent 50µm. 
 
Lastly, to identify the relationship of the smooth muscle to neuronal structures, 
tissue from both ganglionic and aganglionic gut was dual stained with S100 and 
smooth muscle actin (SMA). The ganglia appeared to have a close relationship with 
the smooth muscle in the ganglionic gut and there was is no layer between the two 
tissue types (Figure 5.9 C). However in aganglionic gut there is a space between the 
two tissue types which contains cell nuclei (Figure 5.9 E and F). When compared 
with figure 5.5, where dual labelling has taken place with P75 and S100 it would 
appear that this space is occupied by the ring intensely expressing P75. 
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 5.6 Discussion 
5.6.1 A ring of intense P75 expression surrounds thickened nerve 
trunks 
The thickened nerve trunks identified in both the submucosal and inter-muscular 
layers of aganglionic gut were of a similar appearance in terms of P75 expression to 
those described in the literature in that there was a ring of intense P75 expression 
on the periphery of the structure.(Kobayashi, O'Briain & Puri 1994b). Additionally, 
axons expressing the dopaminergic neuronal marker tyrosine hydroxylase and 
endoneurial P75 positive glia are shown to be deep to the intense ring of P75 
expression. There is some evidence which shows that the fibroblastic cells of the 
perineurium surrounding extrinsic nerves consists of neural crest derived cells 
however more recently lineage tracing has shown that this is not the case.(Hirose, 
Sano & Hizawa 1986; Joseph et al. 2004) Also, using electron microscopy multiple 
layers of perineurial cells can be observed surrounding thickened nerve trunks 
compared to normal extrinsic nerves.(Baumgarten, Holstein & Stelzner 1973) This 
evidence suggests that the thickened rings surrounding the thickened nerve trunks 
are unusual. It is unlikely that these cells are perineurial cells as found in normal 
extrinsic nerves as they express the neural crest marker P75, are thickened 
compared to normal perineurium and express high levels of P75 compared to 
endoneurial tissue within the nerve. On the contrary, the expression of laminin just 
outside the thickened nerve trunks appears to identify basement membranes which 
are in keeping with the structure of a surrounding perineurial layer.  
 It may also be possible that the increased expression is actually ENCC which 
migrated into the gut from the sacral NCC contribution with extrinsic nerves during 
the embryological period, but have failed to differentiate into an ENS.(Erickson et al. 
2012) However it has been reported that this ring of intense P75 expression is also 
seen in mesenteric nerves which are peripheral nerves and therefore this possibility 
would appear less likely.(Kobayashi, O'Briain & Puri 1994b) 
 
5.6.2 The cellular source of aganglionic ENSPC 
The hypothesis that cells of Schwann cell lineage are the source of ENSPC in 
aganglionic gut is supported by the expression of the glial marker, S100, and weak 
P75 expression within the thickened nerve trunks. The intense ring of P75 
expression does not label with S100 however and therefore does not these contain 
Schwann cells. It is therefore possible that cells of this thickened surrounding layer 
around the nerve trunks are the source of ENSPC. However it seems more probable 
from studies showing the ability of glial and Schwann cells to undergo neurogenesis 
that this is not the case.(Joseph et al. 2011; Laranjeira et al. 2011) Additionally, as 
ENSPC from both ganglionic and aganglionic gut behave the same and S100 is also 
expressed within ganglia it is more likely that glial cells are a source of ENSPC from 
both ganglionic and aganglionic HSCR gut. It may also be possibly that ENSPC in 
ganglionic gut are obtained from cells of Schwann cell lineage within the extrinsic 
fibres and not the ganglia. 
 
 5.6.3 The significance of thickened nerve trunks 
It has been shown that thickened nerve trunks in aganglionic HSCR gut are blind 
ending extrinsic nerves but it is not clear why they are present in this gut.(Tam & 
Boyd 1990) In the central nervous system it has been found that blind ending 
nerves which fail to synapse atrophy instead of hypertrophy as in the aganglionic 
gut.(Hefti et al. 1986) It seems logical that the extrinsic nerves increase in size as 
they seek synapses with the ENS however this has not been shown and contrasts 
the behaviour of central neurons in similar circumstances.  
 
5.6.4 Nerve fibres are present in muscular layers of ganglionic and 
aganglionic HSCR gut 
Previous work has found, as expected, that nerve fibres are present within the 
muscular layers in non HSCR gut and ganglionic HSCR gut which appear to connect 
the two layers of the ENS, this was also seen in this study.(Kobayashi, O'Briain & 
Puri 1994b; Matsuda et al. 2006) In terms of the aganglionic gut there was disparity 
in the literature regarding the presence of nerve fibres in this tissue. One study 
reported the absence of these fibres within the muscular layers(Kobayashi, O'Briain 
& Puri 1994b) whereas another group observed the presence of these neurites in 
the aganglionic gut.(Matsuda et al. 2006) It was also found in this study that nerve 
fibres were present within the aganglionic gut in the muscular layers. These fibres 
are likely of extrinsic origin and if functional are likely responsible for the tonic 
smooth muscle contraction seen in HSCR. It is unclear as to whether these fibres are 
 identical in ganglionic and aganglionic gut however if they are it would seem that 
dysfunction seen in HSCR is solely due to the absence of enteric ganglia. 
 
5.6.5 Further work with more extensive HSCR variants 
Unfortunately tissue from HSCR affecting the whole of the colon or beyond was not 
available in our study. It has previously been reported that that interstitial cells of 
Cajal are present in the muscular layers of aganglionic gut in short segment HSCR 
however these cells are absent in the same layers of aganglionic total colonic HSCR 
gut.(Solari, Piotrowska & Puri 2003) It is likely from the findings in chapter 3 
detailing the absence of neural crest derived cells amongst cells isolated from 
aganglionic total colonic HSCR gut that there is also an absence of neurites in the 
muscular layers in this gut too. If this hypothesis is true there is further evidence to 
support different aetiologies in the more extensive forms of HSCR. This is another 
area where further work is required. 
 
 
 
 
 
 
 5.7 Conclusion  
Work in this chapter has added to a limited number of studies which have 
characterised aganglionic HSCR gut. Of particular importance, the presence of 
Schwann cells and neurons has been identified in the thickened nerve trunks which 
are of neural crest origin and support the hypothesis that cells of Schwann cell 
lineage are the source of ENSPC. There are still many unanswered questions 
surround the thickened nerve trunks including their development and function as 
well as new questions about the aetiology of the different extensities of HSCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 6 – Overall discussion, areas for further work 
and conclusion 
6.1 Overview 
This final chapter brings the work carried out in this thesis together in one final 
discussion along with review of the aims of this thesis and new developments in the 
field are addressed. The key areas focussed on are the cellular origin of ENSPC in 
aganglionic gut, the appearance of the thickened nerve trunks and the aetiology of 
HSCR. Finally, areas for further work are identified and the clinical implications of 
work in this thesis when considering a stem cell therapy for HSCR are stated. 
 
 
 
 
 
 
 
 
 
 6.2 Introduction  
As stated in chapter 1, the aim of work carried out in this thesis is to confirm and 
add understanding to the observation that ENSPC can be isolated from short and 
long segment aganglionic HSCR gut. Specifically, the objective has been to locate 
the cellular origin of ENSPC within aganglionic gut so more can be understood about 
how these cells can be controlled, predominantly for safety and efficacy reasons, 
before work can progress to human stem cell therapy trials. Not only has the 
original observation been confirmed, but it has also been shown that the ENSPC 
from aganglionic HSCR gut are neural crest derived and the findings in chapter 3 and 
chapter 5 suggest that these cells are located within thickened nerve trunks which 
are pathognomonic of the aganglionic gut in short and long segment disease.  
 
In addition, chapter 2 identified that horse serum medium is favourable to 
neurosphere medium under adherent conditions for culturing neurospheres. In 
order to explore the possibility of transplantation of neurospheres in HSCR patients 
they must be first cultured, therefore horse serum medium was the only media 
used beyond chapter 2 of this thesis. Furthermore, horse serum medium contains 
fewer components than neurosphere medium, which has been used by our group 
previously.(Almond et al. 2007; Lindley et al. 2008; Lindley et al. 2009) This is likely 
to be advantageous if this work progresses to human trials, where adaption to 
serum free media is required for safety reasons, as there will be fewer components 
to replace. 
 6.3 The cellular source of ENSPC in aganglionic HSCR gut 
Using samples of aganglionic HSCR gut from patients with all variants of HSCR it was 
possible to correlate the presence of thickened nerve trunks and the ability to 
obtain ENSPC, as aganglionic gut from total colonic and total intestinal doesn’t 
contain thickened nerve trunks. However, only two patients with total colonic or 
total intestinal disease were sampled. Subsequently, using cell sorting it was also 
found that P75 positive neural crest derived cells obtained from aganglionic HSCR 
gut differentiate into neurons indicating that ENSPC are of neural crest origin, 
whereas the P75 negative cells did not do this.  
 
In terms of the cellular origin of ENSPC, it has been shown that enteric glia can form 
functional neurons, in vitro, although the ability of these cells to generate neurons 
in vivo has been questioned.(Joseph et al. 2011; Laranjeira et al. 2011) Most 
interestingly, it has very recently been discovered that the progenitors of Schwann 
cells can also act as neuronal progenitors in the developing parasympathetic 
nervous system.(Kalcheim & Rohrer 2014) With this information highlighting glia 
and specifically the Schwann cell lineage as neuronal progenitors it is highly likely 
that Schwann cells located in thickened nerve trunks in aganglionic HSCR gut are the 
source of aganglionic ENSPC. If this is the case then further efforts in this area 
should look at the control of cells of Schwann cell lineage to differentiate into 
neurons which if discovered could open the doors to therapeutic treatment for 
HSCR. 
 6.4 Appearance of thickened nerve trunks 
Thickened nerve trunks present in aganglionic gut of short and long segment HSCR 
are extrinsic, blind ending nerves originating from the pelvic plexus.(Tam & Boyd 
1990) Another group described an intense ring of P75 neural crest cell marker 
expression surrounding these nerves along with weakened expression 
internally.(Kobayashi, O'Briain & Puri 1994b) This thickened ring corresponds to an 
observation that thickened nerve trunks have multiple layers of perineurium 
compared to other extrinsic nerves which have much fewer.(Baumgarten, Holstein 
& Stelzner 1973) It was found in this thesis that there was expression of the 
neuronal and glia markers, tyrosine hydroxylase and S100 respectively, from within 
the trunk where there was also expression of the neural crest marker P75. 
However, surrounding this core there is a ring of intense P75 expression which does 
not express any of the other markers used, including neuronal and glial markers. In 
normal extrinsic nerves the perineurium has been shown using lineage tracing to 
not be of NCC lineage, therefore what we and others have seen is not normal 
perineurium surrounding a thickened nerve trunk as normal perineurium does not 
express P75.(Joseph et al. 2004) The identity of the cells expressing P75 in this 
thickened ring is unclear. However, it is entirely possible that these cells are ENSPC 
as we show that neural crest derived cells from aganglionic HSCR gut differentiate 
into neurons.  
 
 Of particular interest, it was found that there are two populations of cells 
expressing P75 identified by FACS on the aganglionic sample whereas there was just 
one population in the ganglionic sample. In the aganglionic sample, one of 
populations expressed P75 with more intensity than the other, which may 
correspond to the cells of the ring of intense P75 expression seen in the thickened 
nerve trunks. In regards to this, there was no effort made to select only one of 
these populations using cell sorting and this is an area for further work in order to 
narrow down further the source of ENSPC in aganglionic gut. 
 
Using S100 and TH antibodies glia and neurons were identified in the core of the 
thickened nerve trunks. As these nerve trunks are of extrinsic origin the glia 
identified are Schwann cells. This corresponds to an observation of thickened nerve 
trunks using electron microscopy which found Schwann cells in these trunks, but 
most importantly, on ultramorphology they were of immature appearance, similar 
to those found in the developing peripheral nervous system.(Baumgarten, Holstein 
& Stelzner 1973) This makes it more likely when combined with the finding that 
Schwann cells precursors act as neuronal progenitors in the developing 
parasympathetic nervous system  that these Schwann cells are the source of ENSPC 
from aganglionic gut.(Kalcheim & Rohrer 2014)  
 
 
 6.5 Aetiology of HSCR 
Work in this thesis has raised several questions about the aetiology of HSCR. It has 
been shown in small mammal studies that the HSCR phenotype occurs due to 
failure of migration of vagal NCC to the distal gut.(Obermayr et al. 2013) Work in 
this thesis suggests that one type of ENSPC are located within thickened nerve 
trunks in aganglionic HSCR gut however it is unknown whether these are ENCC or 
other neural crest derived cells such as Schwann cells. There is evidence to suggest 
that the sacral contribution of NCC to the ENS travel into the gut via the extrinsic 
fibres.(Erickson et al. 2012) If these cells fail to differentiate and remain as 
progenitors then it is entirely possible that these are the ENSPC we are able to 
obtain from aganglionic HSCR gut. If this is the case, then the aetiology of HSCR may 
include failure of proliferation of sacral NCC with or without failure of migration 
too.  
 
Although it is thought extrinsic nerves hypertrophy as a response to failing to 
synapse it is unclear why thickened nerve trunks are present in aganglionic short 
and long segment HSCR gut.(Hefti et al. 1986) Most interestingly it must be 
considered why these trunks are absent in aganglionic total colonic and total 
intestinal HSCR gut. This would suggest that the aetiology of the more extensive 
disease differs from short and long segment disease. It is possible that the more 
extensive forms are the result of more extensive NCC disease as the ENS and 
extrinsic nerves in the gut have failed to form. On the other hand total colonic and 
 total intestinal HSCR may be due to disease of smooth muscle in the gut which is 
unfavourable to neuronal development as both nervous systems are affected. It is 
already known that short segment HSCR can be caused by an extrinsic defect 
consisting of failure of the EDN3-EDNRB signalling pathway as EDN3 is not produced 
by gut mesenchyme.(Obermayr et al. 2013) This theory is supported by an 
observation that interstitial cells of Cajal are absent in aganglionic gut in total 
colonic and total intestinal HSCR but present in the aganglionic gut in short and long 
segment disease suggesting abnormalities in the smooth muscle in the more 
extensive forms of HSCR.(Solari, Piotrowska & Puri 2003) 
 
6.6 Final conclusion  
In order to develop a stem cell therapy for HSCR the cellular identity of ENSPC 
obtainable from aganglionic gut needs to be established for safety and efficacy 
reasons. Results in this thesis showing that ENSPC are of neural crest origin located 
within thickened nerve trunks, combined with evidence showing that Schwann cells 
have an ability to act as neuronal precursors, makes it likely that cells of Schwann 
cell lineage are the ENSPC we have isolated from aganglionic gut.(Joseph et al. 
2011; Kalcheim & Rohrer 2014; Laranjeira et al. 2011) Other neural crest derived 
cells expressing P75 in thickened nerve trunks are neurons, which can be ruled out 
as ENSPC as only axons and not cell bodies are present in extrinsic nerves, and 
abnormal surrounding perineurial cells which may have a role however little is 
known about this abnormal tissue. 
 Now that it has been established that ENSPC are located within aganglionic gut in 
short and long segment HSCR there are two possibilities in terms of translating this 
work to human HSCR therapy. Firstly, aganglionic gut obtained at pull through 
procedure could be used to obtain ENSPC. Aganglionic neurospheres containing 
ENSPC and their differentiated neurons and glia can then be cultured and implanted 
into the remaining aganglionic internal anal sphincter which is thought to cause the 
long term complications after HSCR surgery. It is then likely that cells within 
neurospheres will proliferate and differentiate to form a functional ENS and 
therefore a functional sphincter. There is a risk with any stem cell therapy that 
uncontrolled proliferation of immature cells will result in tumour formation, this risk 
could be minimalised if cell sorting provided a population of mature neurons and 
glia that form neurospheres without the addition of immature ENSPC too. However, 
if the endogenous ENSPC in the thickened nerve trunks of short and long segment 
HSCR aganglionic gut can be stimulated to proliferate and differentiate in situ then 
it possible that HSCR patients can avoid surgery and undergo medical treatment to 
stimulate development of a functional ENS. 
 
 
 
 
 
 6.7 Future work 
6.7.1 Are cells of Schwann cell lineage the source of ENSPC in 
aganglionic HSCR gut? 
To explore this cell sorting could be used with similar methodology as used in 
chapter 4. However, if a surface receptor glial marker is used which is similar to 
S100 then an isolated sub-population of Schwann cells could be characterised after 
time in culture and the expression of mature neuronal markers could be searched 
for. This would give a definitive answer regarding the cellular origin of ENSPC in 
aganglionic gut. The possible barriers to undertaking this work is the challenge of 
finding a cell surface receptor marker that can be used with FACS successfully and 
the challenges of culturing a small yield of primary cells that is inevitable from such 
a minimal cell sub-population. 
 
6.7.2 Which chemical factors stimulate the differentiation of ENSPC? 
In order to identify therapeutic agents which may have the potential to stimulate 
the development of an ENS in aganglionic gut in vivo a variety of different agents 
must be tested in vitro. There are some agents that seem more likely including 
those which stimulate 5HT4 receptor activation, which has been shown to allow 
enteric neural regeneration in guinea pigs.(Matsuyoshi et al. 2010) Additionally, 
inhibition of the Notch pathway in human ENSPC neurospheres has been shown to 
decrease ENSPC proliferation whilst increasing differentiation in vitro.(Theocharatos 
 et al. 2013) Nevertheless, to comprehensively undertake this work high throughput 
screening may be required using a library of chemical agents. This has been well 
documented in the stem cell field and would efficiently identify chemicals which can 
be further tested and potentially trialled in mouse models of HSCR.(Gupta et al. 
2009) 
 
6.7.3 Suicide gene incorporation into ENSPC and other cells within 
neurospheres 
A key concern with any stem cell therapy is the risk of losing control of a cell type 
after implantation resulting in tumour formation.(Wilkinson, Edgar & Kenny 2012) 
In order to reduce the risk to patients of treatment for what is a benign disease 
there should be a method to control cells post implantation. To achieve this a 
suicide gene could be incorporated into the DNA of all cells before implantation 
which would induce apoptosis by production of the p53 protein for 
example.(Malecki 2012) If there is any concern about uncontrolled cell proliferation 
a known therapeutic agent which activates the gene can be administered. To 
develop this technique, in vitro experimentation is required. A potential problem 
with this idea is, genetic changes in cancerous cells may reduce or abolish the 
effectiveness of the suicide gene. In terms of the method itself careful consideration 
is required to ensure that all implanted cells within a neurosphere are incorporated 
with the gene. 
 
 6.7.4 Implantation of human aganglionic neurospheres into a mouse 
model of HSCR 
It has been shown that florescence labelled mouse enteric neurospheres can be 
transplanted into postnatal mouse gut which then form ganglia and display similar 
electrophysiological functional characteristics to ENS ganglia.(Hotta et al. 2013) 
However, to our knowledge, there have been no studies with a mouse model of 
HSCR such as EDNRB-/- mice and transplantation of enteric neurospheres to assess 
the ability to restore normal functionality in aganglionic gut.(Erickson et al. 2012) In 
particular, aganglionic human neurospheres should be transplanted into the 
aganglionic mouse gut and observation should take place short term, to test the 
efficacy of the treatment and long term, to identify any signs of tumour formation. 
If a stem cell therapy for HSCR is shown to be safe and efficacious in mice then the 
logical progression will be to human clinical trials. 
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Information for Parents of children with 
Hirschsprung’s disease 
 
Your child is being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
Thank you for reading this. 
 
Study Title 
Enteric Nervous System Stem Cell Behaviour in Mature Muscle Models 
 
What is the purpose of the study? 
Your child has Hirschsprung’s disease. In this condition nerve cells are missing from the 
rectum. Current treatment is removal of the affected segment of bowel but even after 
this many children have problems with constipation or soiling. We hope to understand 
how to grow nerve cells to allow us to replace them, so as to improve the treatment for 
children with Hirschsprung’s disease in future. 
 
Why has your child been chosen? 
Because your child is going to have an operation involving removal of a section of bowel. 
This would normally be disposed of at the end of the operation but we would like to use 
a small piece of this tissue to study the nerves and muscle within it. 
 
Does your child have to take part? 
No. It is up to you to decide whether or not you wish your child to take part. If you do 
decide that your child may take part you will be given this information sheet to keep and 
be asked to sign a consent form. Should you not want us to use the specimen in this way, 
there will be no effect on the way in which we treat your child. At the end of our tests, 
the specimen will be disposed of in the normal way. 
 
What will happen to my child if I do take part? 
Your child is going to have an operation in which surgery is performed on the bowel. 
During this surgery a small amount of bowel tissue will be removed and routinely sent for 
tests. We would like you to help us by letting us use two small pieces of this tissue 
(approximately two square centimetres) to grow the nerve cells and muscle cells that are 
contained in the bowel wall.  
 
No extra tissue would be removed and this procedure would not affect our ability to do 
the routine tests on the bowel segment. It will have no effect on your child. 
 
 What are the possible disadvantages and risks of taking part? 
There are no additional disadvantages or risks of taking part. 
 
What are the possible benefits to my child of taking part? 
It is likely that the main benefits of your child taking part will be to future children born 
with Hirschsprung’s disease rather than you directly. However, the information that we 
discover may have direct benefits to your child should we be able to isolate stem cells, as 
in future it may be possible to transplant them. 
 
Will my child’s participation in this study be kept confidential? 
Yes. Your child’s name will not be disclosed outside of the hospital. 
 
What will happen to the results of the study? 
We will publish the results of this work in medical and scientific journals and if you would 
like to know our eventual results please inform us. 
 
Who is organising and funding the research? 
This study is organised and run by Mr Simon Kenny, Consultant Paediatric Surgeon, Alder 
Hey Children’s Hospital, Liverpool and Mr David Wilkinson, Clinical Research Fellow, 
University of Liverpool. The research has been kindly funded by the British Association of 
Paediatric Surgeons and the Royal College of Surgeons of England. 
 
Who has reviewed the study? 
This study has been reviewed by a panel of experts, on behalf of the British Association 
of Paediatric Surgeons and the Royal College of Surgeons of England, who believe that it 
is of the highest standard. It has also been approved by the Liverpool Research Ethics 
Committee. 
 
Contact for further information: 
Mr Simon E Kenny    Mr David Wilkinson 
Consultant Surgeon    Clinical Research Fellow 
Department of Paediatric Surgery  University of Liverpool 
Alder Hey Children’s Hospital   Cellular & Molecular Physiology 
Eaton Rd     Sherrington Buildings 
Liverpool     Ashton Street 
L12 2AP     Liverpool 
      L69 3GE 
 
Tel: 0151 252 5434    Tel: 0151 794 5433 
 
If you have any complaints or concerns about your child’s involvement you can contact 
the Patient Advice Liason Service (PALS): 
PALS Office 
Alder Hey Children’s NHS Foundation Trust 
Eaton Road 
Liverpool 
L12 2AP 
 
Tel: 0151 252 5374/5161 Email: PALS@alderhey.nhs.uk 
  
 
Information for Parents of children without  
Hirschsprung’s disease 
 
Your child is being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will involve. 
Please take time to read the following information carefully and discuss it with others if 
you wish. Ask us if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
Thank you for reading this. 
 
What is the purpose of the study? 
Some children have a condition called Hirschsprung’s disease. In this condition nerve 
cells are missing from part of the bowel. Current treatment is removal of the affected 
segment of bowel but even after this many children have problems with constipation or 
soiling. We hope to understand how to grow nerve cells to allow us to replace them, so 
as to improve the treatment for children with Hirschsprung’s disease in future. 
 
Why has your child been chosen? 
Because your child is going to have an operation involving removal of a section of bowel. 
This would normally be disposed of at the end of the operation but we would like to use 
a small piece of this tissue to study the nerves and muscle within it. 
 
Does my child have to take part? 
No. It is up to you to decide whether or not you wish your child to take part. If you do 
decide that your child may take part you will be given this information sheet to keep and 
be asked to sign a consent form. Should you not want us to use the specimen in this way, 
there will be no effect on the way in which we treat your child. At the end of our tests, 
the specimen will be disposed of in the normal way. 
 
What will happen to my child if they do take part? 
Your child is going to have an operation in which surgery is performed on the bowel. 
During this surgery a small amount of bowel tissue will be removed and routinely sent for 
tests. We would like you to help us by letting us use two small pieces of this tissue 
(approximately two square centimetres) to grow the nerve cells and muscle cells that are 
contained in the bowel wall.  
 
No extra tissue would be removed and this procedure would not affect our ability to do 
the routine tests on the bowel segment. It will have no effect on your child. 
 
What are the possible disadvantages and risks of taking part? 
There are no additional disadvantages or risks of taking part. 
  
 
What are the possible benefits of taking part? 
There will no direct benefits to your child in taking part other than the knowledge that 
they are helping others. 
 
Will my child’s participation in this study be kept confidential? 
Yes. Your child’s name will not be disclosed outside of the hospital. 
 
What will happen to the results of the study? 
We will publish the results of this work in medical and scientific journals and if you would 
like to know our eventual results please inform us. 
 
Who is organising and funding the research? 
This study is organised and run by Mr Simon Kenny, Consultant Paediatric Surgeon, Alder 
Hey Children’s Hospital, Liverpool and Mr David Wilkinson, Clinical Research Fellow, 
University of Liverpool. The research has been kindly funded by the British Association of 
Paediatric Surgeons and the Royal College of Surgeons of England. 
 
Who has reviewed the study? 
This study has been reviewed by a panel of experts, on behalf of the British Association 
of Paediatric Surgeons and the Royal College of Surgeons of England, who believe that it 
is of the highest standard. It has also been approved by the Liverpool Research Ethics 
Committee. 
 
 
Contact for further information: 
Mr Simon E Kenny    Mr David Wilkinson 
Consultant Surgeon    Clinical Research Fellow 
Department of Paediatric Surgery  University of Liverpool 
Alder Hey Children’s Hospital  Cellular & Molecular Physiology 
Eaton Rd     Sherrington Buildings 
Liverpool     Ashton Street 
L12 2AP     Liverpool 
      L69 3GE 
 
Tel: 0151 252 5434    Tel: 0151 794 5433 
 
If you have any complaints or concerns about your child’s involvement you can contact 
the Patient Advice Liason Service (PALS): 
 
PALS Office 
Alder Hey Children’s NHS Foundation Trust 
Eaton Road 
Liverpool 
L12 2AP 
 
Tel: 0151 252 5374/5161 Email: PALS@alderhey.nhs.uk 
 
